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‘Ik heb wel eens pijn in mijn snor,’ zei de walrus. ‘Een
soort doffe pijn. Alsof mijn snor bonst. Zo’n soort pijn.’
‘En ik heb soms schildpijn,’ zei de schildpad. ‘Vooral als
ik op reis moet, ‘s ochtends vroeg.’ Hij zweeg even.
‘Het beste is om dan maar niet te gaan,’ zei hij toen.
Het hert vertelde over de pijn in zijn gewei: ‘Mijn hele
gewei lijkt wel in brand te staan, als ik dat heb.’
De slak zei dat hij nogal eens kramp in zijn steeltjes
had, en de kameel vertelde over onaangename 
tintelingen in zijn bulten.
Het nijlpaard zei: ‘Ik heb hier pijn.’ Hij deed zijn mond
wijd open en wees naar binnen. Iedereen boog zich
voorover om die pijn te zien, maar het was te 
schemerig en te ver om iets te kunnen onderscheiden.
‘Dat is jammer,’ zei het nijlpaard. ‘Want het is wel een
interessante pijn.’
(Toon Tellegen. Uit: Misschien wisten zij alles)
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Abbreviations
ACTH adrenocorticotrophic hormone
CCI chronic constriction injury
βEP β-endorphin
MC melanocortin
MC-R melanocortin receptor
µ-OR µ-opiate receptor
δ-OR δ-opiate receptor
α-MSH α-melanocyte stimulating hormone
POMC pro-opiomelanocortin
S.E.M. standard error of the mean
Definitions
The following definitions of terms for the description
of neuropathic pain syndromes are used according to
the task force on taxonomy of the International
Association for the Study of Pain , the IASP 
Allodynia: pain due to a stimulus that does not nor-
mally provoke pain.
Hyperalgesia: an increased response to a stimulus
that is normally painful 
Neuropathic pain: pain initiated by a primary
lesion or dysfunction in the nervous system.
Nociceptor: a receptor preferentially sensitive to a
noxious stimulus or to a stimulus that would
become noxious if prolonged.
Noxious stimulus: a stimulus that is damaging to
normal tissues.
Pain: an unpleasant sensory and emotional experi-
ence associated with actual or potential tis-
sue damage, or described in terms of such
damage.
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1 Neuropathic pain: symptoms and classification
Probably the best definition of pain was formulated by the International
Association for the Study of Pain: “Pain is an unpleasant sensory and emo-
tional experience associated with actual or potential tissue damage, or
described in terms of such damage”
1
. Acute pain, elicited by the activation
of nociceptors in the skin or other tissues of the body, may function as a
warning of potential or ongoing tissue damage, and thus the ability to expe-
rience pain serves to protect the organism. Typically, pain resolves as the
injury heals. However, in some cases, pain can become persistent, either as a
result of injury so extensive that it surpasses the healing ability of the body,
or as a result of damage to the nervous system itself.The latter type of – mal-
adaptive - pain is known as neuropathic pain, and may result from injury to
the peripheral (e.g. peripheral nerves, plexus, nerve roots) or central (e.g.
spinal cord, brain) nervous system.
Although the causes of nervous system injury may vary, symptoms of neu-
ropathic pain are common and include both negative and positive symp-
toms. Negative symptoms consist of diminished sensitivity to stimuli
(hypoalgesia and hypoesthesia). Positive symptoms include: 1) Spontaneous
sensations: stimulus-independent pain, which can be continuous (often
described as burning, stabbing, cutting, prickling) or paroxysmal (described
as shooting, electric-like), and spontaneous abnormal sensations, such as
numbness, tingling, prickling or itching feelings (dysthesias and paresthesias).
2) Evoked sensations: increased responses to painful stimuli, such as skin
heating and cooling, or strong mechanical stimuli (hyperalgesia) and pain
due to normally non-painful stimuli such as mild warming, cooling or touch
(allodynia).These symptoms are amongst the most serious and invalidating
symptoms of neuropathic pain.They can occur alone or in combination. In
clinical practice, it is very difficult to differentiate between allodynia and
hyperalgesia. Also, because the stimuli are painful, the patient is often diffi-
cult to examine.All symptoms share in common that their distribution pat-
tern is consistent with the underlying neural dysfunction, that is, pain is
experienced in the area innervated by a nerve root (radicular) or peripheral
nerve (dermatome, glove and stocking area).
Because of its heterogeneity, neuropathic pain is difficult to classify. In gen-
General introduction
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eral, neuropathic pain syndromes are classified according to the aetiology and
anatomical distribution of the underlying injury. In table 1 various disorders
that may give rise to neuropathic pain syndrome are listed, this list being far
from complete 
2-4
.Recently,Dellemijn
4
defined three different groups of syn-
dromes, based on the underlying mechanisms. 1) Nociceptive nerve pain,
pain due to an inflammatory process activating the ‘nervi nervorum’, inner-
vating the nerve sheath, epi- and perineurium.This type of pain always orig-
inates in the peripheral nervous system. 2) Complex regional pain syn-
dromes and dystrophies, which may be sympathetically maintained. 3)
Deafferentation pain, pain due to damage to the nervous system, without an
inflammatory component, stemming from either the peripheral or central
nervous system. Other terms used to define central pain are “thalamic pain”
or “dysesthetic pain”
5
.
Not every injury to the nervous system has the same effect, that is, not every
patient with a similar nerve injury develops neuropathic pain, and currently
there are no predictors which patients will be affected.Therefore, at present
there is a tendency towards a more “symptom-and-sign” based approach
6-7
instead of the “cause-and-effect” classification based on aetiology. Similarly,
the efficacy of drugs in different types of human pain syndromes generates
another possible classification of neuropathic pain, based upon the response
to different pharmacological agents
8
. For instance, mechanical allodynia, irre-
Chapter 1
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spective of its cause, may be reduced by NMDA receptor antagonists
9
,
whereas lancinating pain may be best treated with anti-convulsants
10
. Such
an approach might not only improve our understanding of neuropathic pain,
but might also give us a tool to establish the pharmacological treatment that
best fits the individual patient’s needs
11
. However, in the search for potential
new treatment strategies, it is important to understand the pathophysiologi-
cal mechanisms involved in neuropathic pain.
2 Animal models for neuropathic pain
In the investigation of human neuropathic pain it is inevitable to make use
of animal models. In the past decades, numerous animal models with various
lesions to the nervous system have been developed and studied.Here we give
an overview of several of these models.
2.1 Central nervous system lesions
An important cause of chronic central pain syndromes is spinal cord injury
(SCI). Following SCI, neuropathic pain syndromes develop in the majority
of patients
12-14
. It usually presents as a burning or shooting pain and mechan-
ical allodynia in the dermatomes at or below the level of injury. As the
majority of human SCI is due to mechanical trauma, several animal models
have been developed in which a mechanical injury is inflicted upon the
spinal cord, parallel with the clinical situation. The spinal cord contusion
model, in which the injury is inflicted by dropping a weight on the spinal
cord, has been used extensively to study regeneration and return of function
after SCI. Siddall and co-workers have shown that rats with a weight-drop
injury develop signs of neuropathic pain, as indicated by a mechanical allo-
dynia in the dermatomes close to the level of injury 
15-16
. Similarly, hemisec-
tion of the spinal cord at the thoracic level elicited mechanical and thermal
allodynia in all four limbs
17-18.
Watson and colleagues
19
developed a method to produce an ischemic spinal
cord lesion by laser-irradiation of the dorsal horn after systemic injection of
a photopigment, thus causing a photochemical reaction and occlusion of
blood vessels in the radiated area. This type of lesion bears a resemblance to
General introduction
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stroke, which is an important cause of chronic central neuropathic pain in
humans
20
. Indeed, animals with such a photochemically-induced injury
develop a mechanical allodynia that lasted for months 
21-22
.
Although the mechanical and ischaemia induced SCI-models share certain
characteristics with the human situation, the vast extent of tissue damage
associated with these type of lesions make it difficult to study the role of spe-
cific neuronal substrates involved in the related sensory disturbances.
Therefore, Yezierski and Park followed a different approach by simulating
injury-induced elevations of excitatory amino acids and excitotoxic cell
death
23
. After intraspinal injection of the excitatory amino acid agonist
quisqualic acid (QUIS), animals acquire a hypersensitivity to thermal and
mechanical stimulation. Also, increased responsiveness to peripheral input
and higher background activity of spinal sensory neurons have been recog-
nized after QUIS injection
24
, indicating a central hyperexcitability. A differ-
ent approach of mimicking the central sensitized state present in neuropath-
ic pain is the pharmacological removal of inhibitory systems. Intrathecal
administration of pertussis toxin (PTX) inactivates inhibitory G-proteins,
thus blocking inhibitory control and leading to a predominantly excitatory
state. Another means to remove inhibitory control is intrathecal application
of strychnine (STR), thus blocking spinal glycinergic transmission. In rats
or mice, both PTX and STR cause hyperalgesia and allodynia 
25-27
, indicative
of a neuropathic pain state through a direct central mechanism.
2.2 Peripheral nerve lesions
2.2.1 Complete nerve damage
Originally, much insight into the mechanisms of nerve-injury induced pain
has come from Wall’s neuroma model, or experimental anaesthesia
dolorosa
28
, in which the sciatic nerve is transected and ligated. After cutting
the nerve, the animals develop a tendency to bite or automutilate the affect-
ed limb, a phenomenon referred to as autotomy. Although very rare, there
are some reports mentioning autotomy following deafferentation injuries in
humans
29-31
.The question whether this behaviour really is an index of chron-
ic pain, or reflects dys- or anesthesia associated with the nerve injury, has
however met with considerable controversy
32-33
. By applying neurotoxins
prior to a deafferenting nerve lesion, Rodin and Kruger
34
provide evidence
Chapter 1
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that autotomy merely reflects a tendency of the animal to get rid of a den-
ervated, anaesthetic body part, rather than being a response to pain.
However, Kingery and Vallin
35
report a high degree of correlation between
the onset of autotomy behaviour and the development of mechanical hyper-
algesia following sciatic nerve section, suggesting that the autotomy might
reflect a response to pain.The observation that functional deafferentation by
chronic local lidocaine application to the sciatic nerve does not induce auto-
tomy subscribes this view
36
.
Another nerve-transection or neuroma model has been described, involving
the inferior alveolar nerve, which is a sensory branch of the trigeminal
nerve
37
. In humans, this nerve often gets damaged, e.g. after trauma or sur-
gery on the jaw or mouth, sometimes leading to chronic sensory distur-
bances indicative of neuropathic pain.Yet, in the animal model the main out-
come parameters are electrophysiological measurements , making this model
less manageable.
2.2.2 Partial nerve damage
To date, there are three widely used animal models of peripheral neuropath-
ic pain, all involving partial lesioning of the rat sciatic nerve. The chronic
constriction injury (CCI), described by Bennet and Xie
38
is produced by
tying four loosely constrictive ligatures around the sciatic nerve.This evokes
intraneural edema, thus causing the nerve to strangulate within the ligatures.
The animals develop symptoms similar to those found in patients with neu-
ropathic pain, including signs of ongoing, spontaneous pain, and abnormal
responses to both noxious and non-noxious stimuli, e.g. mechanical and cold
allodynia and heat and mechanical hyperalgesia.Although this model proved
to be highly reproducible, attempts have been made to adapt it to a more
standardized level of constriction, by means of applying polyethylene cuffs of
variable diameter around the nerve
39-40
. There was, however, no correlation
between the extent of axonal fiber loss and pain scores, suggesting that mere-
ly changes in the nerve’s properties or its local microenvironment play a key
role in the generation of pain, rather than the degree of axonal alterations.
Two similar animal models, involving partial lesioning of the sciatic nerve are
the spinal nerve transsection model of Kim and Chung
41
and the partial
nerve ligation model of Seltzer et al.
42
The former entails transsection (by
General introduction
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tight ligation) of the L5-L6 spinal nerves, close to the intervertebral foramen
and in the latter a suture is inserted through the sciatic nerve and approxi-
mately 1⁄3 to 1⁄2 of the nerve is tightly ligated.The CCI model results in a dif-
ferential axonal fiber loss, since the ligatures predominantly affect myelinat-
ed fibers.Thus most of the large myelinated Aβ and a large portion of the
thinner myelinated Aδ fibers are lost, whereas a large percentage of the
unmyelinated C-fibers remain intact
43-44
. In contrast, both the spinal nerve
transsection and the partial nerve ligation model produce a partial, non-dif-
ferential axonal loss, leaving the hind paw innervated by a reduced number
of all fiber types.These three models produce similar signs of both sponta-
neous and stimulus-evoked pain, although the magnitude of the different
components could differ between models
45
.
Next to the above-mentioned models, other, less frequently used models
involving partial lesioning of a peripheral nerve have been developed. Sciatic
cryoneurolysis, in which the proximal sciatic nerve is subjected to a cry-
oprobe freeze-thaw-freeze sequence, produces autotomy, signs of sponta-
neous pain and touch-evoked allodynia
46
.A crush injury of the sciatic nerve
has also been used to study neuropathic pain.Allodynia and hyperalgesia fol-
lowing this type of injury have been reported, but with very dissimilar time-
courses
47-49
. Inferior caudal trunk injury
50
, produced by resection of the left
inferior caudal trunk between the S3 and S4 spinal nerves, leads to signs of
neuropathic pain in the rats tail.An advantage of this model is the possibili-
ty of blind behavioural testing, since there is no visible difference between
the tails of neuropathic and sham-operated animals, whereas models involv-
ing lesions of the sciatic nerve usually lead to deformities of the hind paw.
All these models share in common that the nerve lesion occurs in a more or
less acute fashion, whereas in certain human clinical conditions, such as sci-
atica due to a herniated disc or stenosis of the intervertebral foramen, nerve
compression takes place more gradually. By placing a gradual compresion-
onset constrictor around a spinal nerve, Cornefjord and colleagues
51
have
mimicked this condition in the pig. Also, by by placing a silastic tube around
a dog spinal nerve root with a diameter slightly larger than that of the nerve
root, histological and electrophysiological changes develop gradually, over a
period of months
52
.
By loosely ligating the L4 and L5 dorsal root ganglia (DRG), Chatani et al
53
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have developed a model in which the role of the DRG in sciatica can be
investigated. Also chronic DRG compression produced by insertion of a
small stainless steel rod into the L5 intervertebral foramen
54
, may serve as a
model for human low back pain and sciatica.A recent study by Omarker an
Myers
55
showed that combining chronic displacement of the L4 nerve root
and DRG with a herniated nucleus pulposus results in a transient decrease
in thermal threshold, indicative of neuropathic pain.
An animal model resembling human post-herpetic neuralgia is created by
General introduction
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injecting varicella-zoster virus-infected cells into the footpad of the rat’s
hindpaw
56
, leading to allodynia and hyperalgesia in the injected, but not the
contralateral paw
57
.
Whereas the aforementioned models produce a mono-neuropathic pain, in
humans, clinical conditions associated with polyneuropathy, e.g. diabetes or
chemotherapy, can also lead to chronic pain states. Experimental animal
models, giving rise to such a polyneuropathy can also produce a similar
symptomatology. A widely used model to study the pathophysiology of
human diabetes is streptozotocin-induced diabetes in rats. Several reports
have been published demonstrating signs of hyperalgesia and allodynia asso-
ciated with this condition
58-59
.
All these aforementioned animal models thus have many similar features but
also differences and may represent different populations of clinical patients.
They serve as valuable tools in the investigation of pathophysiological mech-
anisms and pharmacology of human neuropathic pain. In table 2 a summa-
ry of the different animal models is presented.
3 Pathophysiology of neuropathic pain
It is beyond the scope of this chapter to give a detailed overview of the cur-
rently known mechanisms underlying neuropathic pain (for review, see
Woolf and Mannion
6
and Attal and Bouhassira
60
). In summary, they include
both peripheral and central systems, as described below.
3.1 Peripheral mechanisms
3.1.1 Primary afferent sensitisation and recruitment of silent
nociceptors
In tissue injury, nociceptors may become sensitised, resulting in a decrease in
the threshold for stimuli and an increased response to suprathreshold stim-
uli. The neurochemical basis for primary afferent sensitisation involves the
release of inflammatory mediators such as amines, prostaglandins,
leukotrienes and bradykinins
61
.
In addition, there are nociceptors that normally have a very high threshold
for activation (so-called “silent” or “sleeping” nociceptors
62
).These receptors
Chapter 1
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can become sensitised, and thus recruited, upon prolonged noxious stimula-
tion, as is the case in tissue damage with the local release of inflammatory
mediators, for which a number of receptors are found on peripheral nerve
fibres
63
.
3.1.2 Sympathetically induced discharges
An interaction between primary afferent terminals and sympathetic post-
ganglionic efferent terminals also plays an important role. Noradrenaline
released from sympathetic terminals via the activation of autoreceptors caus-
es the production of eicosanoids, which diffuse to the sensory neuron, result-
ing in sensitisation
64
. Moreover, damaged sensory neurons become sensitive
to catecholamines by expressing α-adrenoceptors
65
. Nerve injury also
induces sprouting of sympathetic axons into the dorsal root ganglion, form-
ing baskets around the cell bodies of primary afferents
66
. Together, this might
represent a mechanism by which sympathetic activity maintains discharge in
primary afferent fibres.
3.1.3 Spontaneous discharges in damaged primary afferents
Injured axons start discharging spontaneously.After axotomy, the regenerat-
ing nerve forms sprouts. In these regenerating sprouts ectopic discharges are
observed.These can be purely spontaneous (due to instability of the mem-
brane potential) or caused by occult stimuli such as circulating cate-
cholamines or light mechanical stimulation (e.g. the beating of an nearby
arteriole), because these sprouts also become more sensitive to mechanical,
thermal, ionic or catecholamine stimulation
67
.An ongoing local inflammato-
ry process could also contribute to these ectopic discharges, because local
application of eicosanoids to injured primary afferents can cause C-fibre dis-
charge
68
.These ectopic discharges are also observed in the dorsal root gan-
glion, where the cell bodies of the axotomized primary afferents lie
69
.
3.1.4.Collateral sprouts 
Neighbouring undamaged primary afferents form new sprouts that inner-
vate denervated areas of skin. These areas of skin are shown to become
hyperalgesic and allodynic to mechanical stimuli
35,70
. It is not clear whether
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this is a peripheral (these newly formed sprouts can exhibit some of the
abnormalities seen in neuroma sprouts) or central mechanism, or a combi-
nation of both.
Taken together, these changes result in an increased afferent barrage, which
in turn can lead to hyperexcitability of dorsal horn neurons (see below)
3.2 Central mechanisms
3.2.1 Excitotoxicity
A high rate of discharge in damaged small afferent fibres can produce a state
of central hyperexcitability. The abnormal discharge causes an excessive
release of excitatory amino acids (glutamate, aspartate), resulting in high lev-
els of activity of glutaminergic synapses (mediated by the NMDA type
receptor)
71
. Subsequently, small-to-medium-sized neurons in laminae I-III,
presumably inhibitory interneurons, undergo degenerative changes (and
become so-called ‘dark neurons’). This excitotoxicity results in a state of
increased excitability, due to disinhibition
72,73
.
3.2.2 Wind-up
Another mechanism inducing central sensitisation is the so-called “action
potential wind up” or simply “wind up” in which spinal cord neurons
receiving small-fibre input generate more action potentials after each suc-
cessive stimulus of a pulse-volley. The key receptor in this process is the
NMDA receptor
74
.There is evidence that after nerve injury, large myelinat-
ed afferents (of the Aβ type, or low-threshold mechanoreceptors) may also
begin to induce such central sensitization.A switch in the Aβ fibre chemical
phenotype, causing them to adopt a C fiber-like phenotype, is thought to
underlie this phenomenon
75
.
3.2.3 Reorganisation of dorsal horn synaptic connectivity 
After peripheral nerve injury,Aβ fibers begin to sprout into lamina II of the
dorsal horn, where postsynaptic targets usually receive only small afferent
fibre (nociceptor) input
76
.This reorganisation may contribute to the touch-
evoked pain that can follow nerve injury, because an area that normally only
receives noxious information now obtains input from non-noxious tactile
Chapter 1
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stimuli.The misinterpretation of this information by the nervous system as
noxious input thus provides an anatomical basis for mechanical allodynia.
3.2.4 Spontaneous discharge and altered thresholds
Spinal neurons that connect with axotomised primary afferents (thus lack-
ing input from the periphery) often discharge spontaneously. Cells receiving
input from uninjured neighbouring axons may show abnormal responses
and lowered thresholds. Similar abnormal responses and altered thresholds
are also observed at higher levels, such as in spinothalamic tract neurons and
in the thalamus
77-79
. It thus appears that central homeostatic mechanisms
detect the failure of input and increase the excitability of central cells in an
attempt to compensate for the diminished input (for review, see Wall
80
).
3.2.5 Neuropeptide plasticity
In addition to the above-mentioned changes, the levels of several neuropep-
tide genes and their products are regulated in response to nerve injury.This
neuropeptide plasticity can also contribute to the altered transmission of sen-
sory information observed in neuropathic pain, because neuropeptides mod-
ulate neuronal activity in conjunction with the neurotransmitter with which
they are colocalized.Thus by acting as neuromodulators they fine-tune the
direct communication between neurons.A main event in neuropeptide plas-
ticity is the so-called phenotypic switch of primary afferents, as reflected by
an altered expression of neuropeptides, which is often accompanied by
changes in their receptor levels in the dorsal horn (reviewed in Hokfelt et
al.81).
Substance P and calcitonin-gene-related peptide (CGRP) are normally
expressed by thin primary afferents conveying information from nocicep-
tors. CGRP in sensory primary afferent neurons has an excitatory effect on
postsynaptic neurons and potentiates the effect of substance P in the rat
spinal dorsal horn
82
.After peripheral nerve injury, the levels of these peptides
are markedly decreased in primary afferents and in the dorsal horn
83-85
.Thus
the two main excitatory peptides involved in the transmission of nociceptive
information to the dorsal horn are down-regulated in a neuropathic state. In
adjacent intact nerves, however, CGRP is upregulated, which could con-
tribute to the hyperexcitability of dorsal horn neurons
86
. Morever, a subpop-
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ulation of dorsal root ganglion neurons associated with large myelinated
fibres starts to synthesise these peptides
82,87
.
Different response patterns have been described for a group of peptides that
are normally almost non-detectable in small-diameter primary afferents.
After nerve injury there is a marked increase in the level of galanin, in both
injured and spared dorsal root ganglion neurons
88-90
. Galanin has a predomi-
nantly inhibitory effect
91
and reduces the activity of wide-dynamic range
neurons
92
. However, galanin is also reported to be involved in the facilitation
of nociceptive transmission
93
and increases the release of substance P evoked
by stimulation
94
.Vasoactive intestinal polypeptide (VIP) and pituitary adeny-
late cyclase-activating peptide (PACAP) are also up-regulated after periph-
eral nerve injury83-95. Studies of nociceptive responses have revealed an exci-
tatory role for VIP 96,97, and it has been suggested that this peptide can take
over the role of substance P, which is down-regulated in nerve injury, and
thus maintain nociceptive transmission in the dorsal horn98. PACAP, which
belongs to the same peptide superfamily as VIP95, has an excitatory effect on
spinal cord function as well99,100, similar to that of the above-mentioned pep-
tides.
This list of neuropeptides that undergo up-regulation or down-regulation
after nerve injury is far from complete; e.g. alterations in neuropeptide Y
101,102, cholecystokinin 103,104, and somatostatin105 have been reported as well.
These changes in the levels of neuropeptide messengers reflect a complex
adaptive response of the organism to neuropathic conditions, and might con-
tribute to the hyperalgesia seen in patients with neuropathic pain.
Another group of neuropeptides not mentioned until now is the
melanocortins. These peptides might too play a role in nociception, as
explained below.
4 The melanocortin system in pain
The melanocortins comprise a group of natural peptides all derived from the
precursor molecule pro-opiomelanocortin (POMC), and various syntheti-
cally derived related peptides. In the anterior lobe of the pituitary gland
POMC is processed to form the melanocortin adrenocorticotropic hor-
Chapter 1
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mone (ACTH), the effects of which on the adrenal gland have been long
known. POMC is also expressed in the pituitary intermediate lobe, where it
is processed to form the melanocortins ACTH, β-MSH and α-MSH, a pep-
tide which plays an important role in skin pigmentation. However, aside
from these effects on peripheral tissues, direct effects of melanocortins on the
nervous system have been described as early as the late 1950’s 
106,107
.
Demonstration of immunoreactivity for α-MSH
108
and ACTH
109
, as well as
the expression of POMC in the brain
110
indicated that the nervous system
has its own melanocortin system, distinct from that in the pituitary. Since
then, a wide variety of effects of melanocortin has been described, including
effects on inflammation, fever, nerve regeneration, grooming, social behav-
iour and regulation of body weight (for review see Adan
111
, de Wied
112
).
An additional intriguing effect of the melanocortin system is its functional
interaction with the opiate system, as suggested by several lines of evidence.
Electrophysiological studies have demonstrated that melanocortins can block
morphine-induced depression of evoked potentials in frog and cat nervous
tissue
113,114
. Indications that melanocortins interfere with the effects of opiates
also come from pharmacological studies. Intracerebroventricular (i.c.v.) or
peripheral administration of melanocortins, prior to or simultaneously with
morphine, attenuates the analgesia induced by morphine
115-118
. Repeated
administration of morphine leads to a reduction of its analgesic potency, and
an apparent increase in the potency of naloxone to block the effects of mor-
phine. The development of this opiate tolerance can be inhibited by
melanocortins
118,119
. Also, melanocortins can attenuate the acquisition of
heroin self-administration
120
, and counteract opiate addiction (for review see
Alvaro et al.
121
), as demonstrated by the induction of withdrawal-like symp-
toms in morphine-dependent
122
and drug-naïve
123
rats.
Apart from their interactions with the opiate system, melanocortins are also
known to have direct effects on nociception. I.c.v. administration of 0.1-10
µg α-MSH in rats induced hyperalgesia in the tail-flick test, an effect lasting
for 20 (0.1-1 µg) to 80 (10 µg) min124. Similar results were obtained with 20-
50 µg i.c.v. administered ACTH, which induced hyperalgesia in the hot-
plate and tail-shock tests in the rat, an effect which lasted for 80 min
125
. In
the hedgehog, high doses of peripherally administered ACTH also produced
hyperalgesia
126
. Much lower doses of ACTH (0.5 and 1.0 µg) also caused
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hyperalgesia, as indicated by decreases in ear withdrawal latency from heat in
the rabbit
127
, although a similar dose (1.0 µg) had no effect on tail-flick laten-
cy in the rat
117
. Also i.c.v. α-MSH (0.25-2.0 µg) had no effect on ear with-
drawal latency in the rabbit
127
.A few reports claimed that melanocortins can
also produce hypoalgesia. Ohkubo and colleges showed that i.c.v. adminis-
tration of 0.1-10 µg α-MSH in mice induced analgesia in the hot-plate test,
an effect lasting 20 min 
128
. Microinjection of α-MSH in the periaqueductal
grey matter also significantly reduced responsiveness to pain
129
.
In spite of the growing list of the biological actions of melanocortins, the
molecular mechanisms underlying these effects were largely unknown. Only
since the 1980s have brain binding sites for the melanocortins been demon-
strated
130,131
. Soon thereafter, the first melanocortin receptors were
cloned
132,133
, which started a new era in the field of melanocortin research. So
far, five melanocortin receptor subtypes have been identified, all members of
the G-protein-coupled receptor superfamily (for review see
Cone
134
,Tatro
135
). Of these five subtypes, the melanocortin MC3 and
melanocortin MC4 receptors are expressed in the nervous system. The
melanocortin MC3 receptor has a limited distribution in the brain, and is
found mainly in the hypothalamus, thalamus, brainstem and cortex.
Compared to the melanocortin MC3 receptor, the melanocortin MC4
receptor has a much more widespread distribution in virtually every region
of the brain
136-140
. Moreover, it is the only subtype to be expressed in the
spinal cord
138
. Binding of a radioactively labelled α-MSH analogue to rat
spinal cord demonstrated that melanocortin MC4 receptors are expressed
most abundantly in the superficial dorsal horn (lamina I and II) and in the
grey matter surrounding the central canal (lamina X), areas that are impor-
tant in nociceptive transmission
141
. In addition, mRNA encoding for POMC
has been demonstrated in spinal cord
141,142
and the nucleus tractus solitarius
has been suggested as a possible source of POMC projections to the spinal
cord
143
. Interestingly, electrical stimulation of the nucleus tractus solitarius has
been shown to produce pronounced analgesia
144
, suggesting that the POMC
system may play a role in modulating nociceptive transmission.
Immunoreactivity for the POMC-derived peptides ACTH and α-MSH has
been detected in the dorsal horn and lamina X
142,143
.Together, the presence
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of melanocortin MC4 receptors, mRNA and cleavage products of POMC
strongly suggest the presence of a functional melanocortin system in the rat
spinal cord.The expression of the melanocortin MC4 receptor in nocicep-
tion-associated areas in the spinal cord suggests that this spinal melanocortin
system might play a role in pain, and that the melanocortin MC4 receptor
might be a potential target in the ongoing search for new analgesics.
None of the natural melanocortin peptides show distinct selectivity for one
of the melanocortin receptors, although γ-MSH is relatively more selective
for the melanocortin MC3 than the melanocortin MC4 receptor
145
.The syn-
thetic peptide [Nle4,D-Phe7]α-MSH is a very powerful agonist for all
melanocortin-receptor subtypes and can be used as a radioligand when
labelled with iodine.Another strong synthetic melanocortin receptor agonist
is cyclo-[Nle4,Asp5,D-Phe7,Lys10]α-MSH (melanotan II).A ligand with a
significant higher affinity and potency at the melanocortin MC4 receptor
than at the melanocortin MC3 receptor is cyclo-[Nle
4,Asp5,D-
Tyr7,Lys10]α-MSH (D-Tyr-melanotan II). In contrast, Ac-[Nle3]γ2-MSH
(Nle-γ-MSH) is a ligand with higher selectivity for the melanocortin MC3
receptor
146
.
A derivative of melanotan II, cyclo-[Nle4,Asp5,D-Nal(2)7,Lys10]α-MSH
(SHU9119), has been shown to be a potent competitive melanocortin
receptor antagonist 
147
.With the availability of these ligands, it became pos-
sible to investigate in further detail the role of the melanocortin MC4 recep-
tor  in various melanocortin actions.
5 Aims and outline of the thesis
As summarized in the previous paragraphs, much progression has been made
in the understanding of factors precipitating neuropathic pain. However,
despite extensive clinical and experimental research, we are still limited in
our ability to successfully treat patients suffering from this condition. Further
research directed towards a better understanding of the pathophysiological
mechanisms underlying this condition is warranted, and will hopefully lead
to new treatment strategies for neuropathic pain.The main objectives of the
studies presented in this thesis are to investigate whether the MC system is
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involved in neuropathic pain and how MCs can modulate neuropathic pain
symptoms.
Much of our insight into the mechanisms of neuropathic pain has come
from studies employing various animal models. The most commonly used
models include spinal nerve transsection
41
, partial ligation of the sciatic
nerve
42
and a chronic constriction injury (CCI) of the sciatic nerve
38
(see also
table 2).
In the experiments described in this thesis the CCI model is used. In chap-
ter 2 we extensively characterize this model with respect to the time course
of different motor and sensory disturbances.We studied the same outcome
parameters after a crush injury to the sciatic nerve, a model often used to
study nerve regeneration. We demonstrate that after a sciatic nerve crush
neuropathic pain symptoms, comparable to those in the CCI model, devel-
op.Amongst these symptoms is an exaggerated response to light mechanical
stimuli, referred to as mechanical allodynia. Assessment of mechanical allo-
dynia is usually performed by means of von Frey filaments. In chapter 3 we
present a study describing an alternative way of assessing mechanical allody-
nia, by CatWalk automated gait analysis. We demonstrate a high degree of
correlation between different CatWalk parameters and withdrawal thresh-
olds to von Frey stimulation.
As outlined in the previous section, melanocortins have been demonstrated
to play a role in nociception and to functionally interact with the opiate sys-
tem. In chapter 4 and 5 we investigate the involvement of the spinal MC sys-
tem in neuropathic pain.We therefore administered different MC-R agonists
and antagonists to CCI rats, both in an acute and chronic administration par-
adigm. Based upon the results of these studies we conclude that the spinal
MC system undergoes plastic changes in neuropathic pain and that antago-
nism of the MC4-R can reduce the associated cold and mechanical allody-
nia. We hypothesize that these effects are explained by an interaction
between the opiate and MC system, whereby blockade of the MC system
reveals the anti-allodynic effects of tonic endogenous opiate receptor activa-
tion.
In chapter 6 we studied such a possible interaction between the MC and
opiate system at the spinal level.The main findings and implications of these
studies are summarized and discussed in chapter 7.
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Abstract
This study provides an extensive comparison of the motor and sensory disturbances fol-
lowing two types of lesion of the sciatic nerve: the chronic constriction injury (CCI), which
serves as a model for neuropathic pain, and the crush injury, a model widely used to study
nerve regeneration.
Initially, there was a severe loss of motor function with both lesions, as measured by the
sciatic function index, toe spreading and open field locomotor behaviour. In the CCI group,
motor function remained impaired for over 70-80 days, whereas in the crush group, motor
locomotion gradually recovered within the first 28-35 days post-injury.
CCI rats developed signs of hyperalgesia and allodynia to cold, mechanical and chemical
stimulation already within a few days after lesioning, whereas in the crush group there were
no signs of sensory abnormalities at this time. However, after 29-35 days, they developed
sensory abnormalities similar to those in the CCI group, this onset coinciding with the
return of sciatic motor function.This suggests that, analogous to the CCI lesion, a neuro-
pathic pain syndrome develops after sciatic nerve crush, which can only be detected after
regeneration and re-establishment of a functional contact between the periphery and the
central nervous system, allowing the animal to perceive stimuli applied to the hindpaw.
The above data suggest that the sciatic nerve crush might provide an additional useful tool
in the study of neuropathic pain.
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Introduction
Following a peripheral nerve injury, in humans sometimes a painful syndrome
develops.This neuropathic pain is characterised by spontaneous pain in combi-
nation with allodynia and hyperalgesia.A widely used animal model to study this
condition is the chronic constriction injury (CCI)
1
, in which 4 ligatures are
loosely tied around the sciatic nerve.The model induces severe sensory abnor-
malities, closely mimicking the clinical symptoms of neuropathic pain, as well as
motor deficits
1,2
.The pathogenic mechanisms underlying neuropathic pain in the
CCI model have been studied extensively, and comprise dysfunctions both in the
peripheral as well as in the central nervous system
3
.Histologically, associated with
this lesion is an extensive axonal loss, predominantly of the Aβ-type and , to a
lesser extent, the Aδ type4,5.Thus the periphery is innervated by C fibers and a
largely reduced number of Aδ fibers6.
Another experimental nerve lesion producing extensive fibre loss is the sciatic
nerve crush
7-9
.As with the CCI lesion, the surrounding nerve sheath is not dis-
rupted, thus allowing guidance of the outgrowing axons during regeneration and
reconnection of distal targets. The sciatic nerve crush is a much used animal
model to study nerve regeneration, of which the extent and speed of regenera-
tion is usually defined by the return of sensory and motor function
10,11
. However,
only few studies using the crush model specify the different sensory modalities
or focus on possible pain-related behaviours associated with the lesion
12-14
.
The similarities between the CCI and crush model raised the question to what
extent the crush lesion produces symptoms of neuropathic pain, as seen in the
CCI model. Here we systematically compare the two models with regard to the
temporal correspondence between motor function recovery and changes in
thresholds to different painful and non-painful stimuli.
Materials and methods
All procedures in this study were performed according to the Ethical Guidelines
of the International Association for the Study of Pain
15
and approved of by the
Ethics Committee on Animal Experiments of Utrecht University.
CCI and crush injury
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Animals
Fifty male Wistar rats weighing 250-300 g at the start of the study were used.
Animals were housed in groups of 2-3 in plastic cages on sawdust bedding.
They were kept at a 12/12hr light/dark cycle, with food and water available
ad libitum.Animals were randomly divided into 4 groups (N=12-13).
Surgery
Animals were anaesthetised with a single subcutaneous injection of
Hypnorm (Janssen Pharmaceutical Ltd., Beerse, Belgium), containing 0.315
mg/mL fentanyl citrate and 10 mg/mL fluanisone, diluted in saline (1:2, 0.3
ml/100 g bodyweight).
In 38 animals the right sciatic nerve was exposed at mid-thigh level by blunt
dissection. Hereafter, in one group of animals (N=13) the nerve was chron-
ically constricted by placing 4 loose ligatures of 4-0 chromic catgut around
the nerve, as previously described by Bennet and Xie1 (CCI-group). In the
second group (N=13) the nerve was crushed by tightly squeezing it with a
forceps for 30 seconds (the distance between the lesion site and the mid-
plantar skin was 7.5 cm), as described by de Koning et al10 (crush-group).
In the third group (N=12) the nerve was exposed for 5 minutes, without lig-
ating or crushing it (sham-group).
Subsequently the incision was closed with silk sutures and the animals were
allowed to recover for a 2-3 day period.A group of animals (N=12) which
underwent no surgery was also included (control group).
General observations
As a measure of general health, bodyweight was monitored twice weekly for
the first 5 weeks, and weekly thereafter. Autotomy was scored as follows: 0;
no autotomy, 1; autotomy of one or more toenails, >1; autotomy of one or
more toes (adapted from Wall et al.16). Animals showing signs of autotomy
were closely monitored and excluded from testing in case of severe damage
to the paw.
Test procedures
Testing started at post-operative day (p.o.d.) 3 and continued until p.o.d. 84.
The following tests were performed:
Chapter 2
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1 Locomotor testing
1.1 Sciatic Function Index
In order to quantify disturbances in walking patterns we used the Sciatic
Function Index (SFI). In short, after dipping their hind paws in developing
fluid we let the animals walk over a strip of photographic paper, thus creat-
ing black footprints on the paper. Four measurements were taken from both
the normal (N) and the experimental (E) paw: IT (distance between the 2nd
and 4th toe),TS (distance between the outer toes), PL (foot print length) and
TOF (distance to opposite foot).The SFI was calculated as follows:
SFI = (EIT-NIT/NIT) + (ETS-NTS/NTS) + (NPL-EPL/EPL) +
(ETOF-NTOF/NTOF) * 55
A score of 0 ± 10 indicates a normal function of the sciatic nerve, whereas a
score of –100 or less indicates a complete loss of function (for further details,
see de Medinacelli et al.17).
1.2 Open field locomotor performance
To analyse locomotor recovery animals were observed in an open field.We
used a scoring system in which individual symptoms were scored together
with their frequency of occurrence. Sets of these symptoms were ranked
according to severity of disability, analogous to the Basso, Beattie, Bresnahan
(BBB) locomotor rating scale18. Possible scores ranged from 0 (paralytic drag-
ging of the operated hind limb) to 14 (normal gait) (see Table 1).
1.3 Toe spreading
To quantify the extent of spontaneous toe spreading the animals were held
in a vertical position that causes them to flex the hind paw and spread their
toes. The difference in distance between the outer toes from the right
(experimental) foot was measured in mm, as described by Bijlsma et al.19
2 Sensory testing
2.1 Cold stimulation test
Withdrawal latency to a cold stimulus was measured by immersing the hind
paws into a 4.5°C or a 10°C water bath, as previously described20. Upon
immersion of the paw an electronic circuit including a clock was closed.
Withdrawal of the paw resulted in a discontinuation of the circuit, which
CCI and crush injury
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stopped the clock, thus allowing a careful registration of the withdrawal
latency. Cut-off time was set at 10 sec. Interval time between consecutive
tests was at least 10 min. to allow restoration of original foot temperature.
2.2 Mechanical stimulation test
Foot withdrawal threshold in response to a mechanical stimulus was deter-
mined using a series of von Frey filaments (Stoelting,Wood Dale, IL), rang-
ing from 1.12 to 52.15 g.Animals were placed in a plastic cage with a metal
mesh floor, allowing them to move freely.They were allowed to acclimatise
Chapter 2
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Table 1. Scoring of open field locomotor performance
* occasional: < 50%, frequent: 51-94%, continuous: ≥95% of the observation time
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to this environment prior to the experiment. Von Frey filaments were
applied to the mid-plantar surface of the both feet through the mesh floor.
Each probe was applied to the foot until it just bent, and kept in this posi-
tion for 6-8 s21.The smallest filament that elicited a foot withdrawal response
was considered the threshold stimulus.
2.3 Chemical stimulation test
A 5 µl drop of 50% mustard oil (n-allyl-isothiocyanate (Sigma) in ethanol)
with 0.1% methylene blue added to visualise spreading was applied to the lat-
eral dorsum of the right hind paw, as described by Bennet and Xie1.The ani-
mal was then placed in an open field and observed for two minutes. During
this time the total number of the following responses to the mustardoil was
recorded: shaking the paw, tapping it on the floor and licking the paw.
Statistical analysis
All data are plotted as mean ± standard error of the mean (S.E.M.), for visu-
alisation purposes.
Differences in bodyweight, SFI, toe spreading and number of responses to
mustardoil application were analysed using a repeated measures analysis of
variance. For post-hoc analysis of group differences a Students t-test (SFI) or
Student-Newman-Keuls test (other) was performed.
All other data were analysed using non-parametric tests. For the von Frey
stimulation absolute applied forces in g are plotted. In order to obtain a lin-
ear scale of applied force the logarithm of the applied force was calculated
and statistical analysis was performed on the transformed data. Overall group
differences in von Frey and temperature stimulation tests were analysed by a
Kruskall Wallis test. For analysis of differences in open field locomotor per-
formance scores and mechanical or cold withdrawal responses, a Mann-
Whitney U test was performed, with Bonferroni-correction when necessary.
Results were considered significant when p<0.05.
For open field locomotor performance scores 95% confidence intervals (CI)
were calculated and scores were considered significantly different from max-
imum possible score if 14 was not within the 95% CI.
CCI and crush injury
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Results
Exclusion of animals
One sham animal died during anesthesia, thus rendering a sham-group of
N=11. On p.o.d. 17 one animal in the crush-group was excluded due to
severe autotomy and inflammation of the right hindpaw. On p.o.d. 51, five
animals of each group were sacrificed for purpose of histology (manuscript
in preparation).
General observations
Bodyweight gradually increased throughout the study.There were no signif-
icant differences in bodyweight between groups at any time point.
Autotomy of the affected hindpaw was observed in both the crush and CCI
group. The time of onset as well as the total number of animals showing
autotomy differed between the two groups, with the crush group showing
earlier and more autotomy. In this group the first signs were seen already at
p.o.d. 7 and the number of animals displaying autotomy reached a maximum
at p.o.d. 14 (8 out of 13 animals). In the CCI group onset was at p.o.d. 14
and the maximum (5 out of 13 animals) was reached only at p.o.d. 31 (fig.
1). Overall, autotomy in both groups was mild. Only a few animals reached
a score of >1, two in the CCI group and two in the crush group, of which
one was sacrificed because of the severity of autotomy.
1 Locomotor testing
There were no significant differences between control and sham animals at
any time point in any of the locomotor tests.
1.1 Sciatic Function Index
Already from the first testing day after surgery (p.o.d. 3) SFI in the CCI
group was significantly lower than in the crush group (-101.0 ± 2.3 vs. -93.4
± 1.4, respectively) and remained lower until p.o.d. 73. In contrast to the
CCI group, recovery in the crush group was much faster and already from
p.o.d. 30 SFI in the crush-group was within normal limits (fig. 2A).
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1.2 Open field locomotor performance
P.o.d. 7 was the first day the animals’ locomotor performance was observed
in an open field. Locomotor performance scores in the CCI and crush
groups were decreased to 4.6 ± 0.6 and 7.2 ± 0.6, respectively. Starting at
p.o.d. 35 crush scores did no longer significantly differ from maximum score
(14). CCI values remained significantly lower until p.o.d. 70 (fig. 2B)
1.3 Toe spreading
Toe spreading in the control and sham animals displayed a gradual increase dur-
ing the first 10 days, due to growth of the animals.At p.o.d. 3 toe spreading in
CCI and crush group was decreased to 13.2 ± 0.3 and 14.2 ± 0.3 mm, respec-
tively. After p.o.d. 17 toe spreading in the crush group rapidly increased and
from p.o.d. 28 no longer differed from control values. In contrast, in the CCI
group, toe spreading remained significantly smaller until p.o.d. 63 (fig. 2C).
CCI and crush injury
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Figure 1.
The onset and
extent of autoto-
my behaviour after
crush or CCI of
the scia-tic nerve.
The total number
of animals showing
different levels of
autotomy is depict-
ed. Autotomy
scores are adapted
from Wall et al 16.
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Figure 2.
Locomotor testing
(A) Sciatic Function
Index.The grey area
indicates the range of
SFI in normal rats (0
± 10). (for details, see
de Medinacelli et
al.,17). (B) Open field
locomotor perform-
ance scores (see Table
1). Maximum possible
score was 14, indicat-
ed by the dotted line.
(C) Toe spreading.The
distance between the
outer toes of the
experimental hindpaw.
Measurements were
taken in rats held in
vertical position and
actively spreading their
toes.
Locomotor recovery
in the crush-group
took place between
post-operative days
28 (toe spreading)
and 35 (open field). In
the CCI group func-
tional recovery
occurred later and
scores remained
below control level
until p.o.d. 63 (toe
spreading) through 73
(SFI).
Data represent mean
± S.E.M. of 12 (con-
trol), 11 (sham) or 13
(crush and CCI) rats
each. (º p < 0.05
crush vs. sham; * p <
0.05 CCI vs. sham, #
p < 0.05 CCI vs.
crush).
A
B
C
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2 Sensory  testing
There were no significant differences between control and sham animals at
any time point in any of the sensory tests.Also there were no differences in
withdrawal latencies of the left, unoperated hind paw from a mechanical or
cold stimulus between groups at any time point.
2.1 Temperature stimulation test
Already from the first testing day after surgery (p.o.d. 4) CCI animals devel-
oped a cold allodynia, as indicated by a significant decrease in withdrawal
latency to a 4.5 °C stimulus (3.2 ± 1.0 s, cut-off value was 10 sec).
Withdrawal latencies in this group remained lower when compared to sham
values until p.o.d. 77. Starting at p.o.d. 29 crush animals also developed a sig-
nificant cold-allodynia.Withdrawal latencies decreased to a minimum of 2.4
± 1.1 s and gradually returned to normal level towards the end of the test-
ing period (fig. 3A).
Similar results were obtained when temperature was increased to 10 °C (data
not shown).
2.2 Mechanical stimulation test
Mechanical allodynia developed in the CCI group, as demonstrated by a
large decrease in withdrawal threshold to von Frey stimulation starting at
p.o.d. 8 and reaching a minimum of 10.9 ± 1.8 g.Also in the crush group a
mechanical allodynia developed. Thresholds were significantly lower than
sham values starting at p.o.d. 29 and reached a minimum of 12.8 ± 1.6 g.
In both CCI and crush animals the mechanical allodynia gradually resolved
over the 12 week postoperative period (fig. 3B).
2.3 Chemical stimulation test
Both sham and control groups showed a small, gradual increase in the num-
ber of responses during the first 2 weeks. No mustardoil was applied
between p.o.d. 49 and 77 and hereafter the number of responses was again
reduced to initial levels in these groups. Already at p.o.d. 3, the first testing
day after surgery, CCI animals exhibited significantly more behavioural
responses upon application of mustardoil as compared to the sham group.
Also in the crush group a hyperalgesia developed. The total number of
CCI and crush injury
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responses in this group was significantly increased at a single time point (p.o.d.
17) and thereafter from p.o.d. 35 until p.o.d. 49. From p.o.d.77 on, the num-
ber of responses had normalised in both CCI and crush animals (fig. 3C).
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Figure 3.
Sensory testing
(A) Cold stimulation.
Withdrawal latencies of the
experimental hindpaw upon
immersion in a 4.5 ºC
waterbath. Cut-off latency
was 10 s. (B) Mechanical
stimulation.Withdrawal
thresholds of the experi-
mental hindpaw to von Frey
filaments (ranging from 1.12
to 52.15 g). (C) Chemical
stimulation.The total num-
ber of behavioural respons-
es upon application of 5 ml
of 50% mustardoil to the
dorsum of the experimen-
tal hindpaw was deter-
mined. Responses consisted
of shaking, licking and tap-
ping the paw and were
counted during two min-
utes.
CCI rats showed cold and
mechanical allodynia and
chemical hyperalgesia
already from the first testing
day after lesioning.Animals
in the crush group devel-
oped similar sensory abnor-
malities between p.o.d. 29
(cold and mechanical stimu-
lation) and 35 (mustardoil).
Data represent mean ±
S.E.M. of 12 (control), 11
(sham) or 13 (crush and
CCI) rats each (º p < 0.05
crush vs. sham; * p < 0.05
CCI vs. sham, # p < 0.05
CCI vs. crush).
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Discussion
In the study presented here we describe the time course of different senso-
ry and locomotor functions, as well as the development of a neuropathic
pain syndrome, after a crush injury to the sciatic nerve.
At the first experimental day after surgery, the SFI in crush rats had decreased
to approximately –95%, indicating that an effective nerve injury had been
accomplished22. During regeneration, return of function is reflected in an
increase in SFI towards 0%10,23.Toe spreading and the open field locomotor
performance test (which contains an evaluation of toe spreading with the
higher scores) both include an assessment of the function of the interosseus
muscles, innervated by distal branches of the sciatic nerve. Normalization of
these functional tests thus indicates a successful regeneration of the most dis-
tal parts of the sciatic nerve19,24. In our rats, normalisation of these locomo-
tor function tests occurred between postoperative days 28 and 35, which is
in good agreement with previous studies22,23,25,26. Since in the present study
autotomy was limited and usually confined to biting off one ore more toe-
nails without damage to the skin or flesh (except in one animal which was
sacrificed for this reason), it had no influence on the outcome of the func-
tional tests we used.
Upon a sciatic crush injury a profound sensory loss occurs, as has been
demonstrated by using electrical stimulation of the foot sole10,23, or mechan-
ical or thermal stimulation26,27. In the present study there were no differences
in responses to cold and mechanical stimulation between control, sham and
crush rats, early after surgery. Most animals in these groups did not respond
to the highest filament tested (52.15 g) or demonstrate a positive withdraw-
al upon cold stimulation within 10 s (cut-off value).Thus, we were unable
to detect a decreased sensitivity to these stimuli in crush animals compared
to controls. Since a positive response consists of a flexion of the limb, away
from the stimulus, an absence of withdrawal in crush animals cannot be sub-
scribed to the severe motor damage associated with the lesion, as the femoral
nerve which is needed for hip flexion is still intact.There were also no sig-
nificant differences in the number of responses to mustard oil application
between crush and control rats early after surgery.The fact that the number
of responses was not lower in the crush group compared to control values,
CCI and crush injury
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as would be expected with a complete lesion of the sciatic nerve, might be
explained by a spread of the oil to skin areas innervated by the adjacent
saphenous nerve.Also, mustard oil has a very strong smell which could cause
the animal to shake and lick its paw in an attemp to get rid of the oil. In
contrast to early after surgery, the crush animals demonstrated increased
responses to all sensory tests after postoperative day 29, temporally corre-
sponding with the restoration of locomotor function.
Through analysis of the return of positive reactions to electrical stimulation
of the sole of the foor after a sciatic nerve crush, de Koning et al.10 estimat-
ed axonal growth to be 2.8-2.9 mm/day. By using immunohistochemical
methods,Verdu and Navarro9 have estimated similar regeneration rates, for
both sensory and alphamotor fibers They reported an interval of about 2-3
days between histological signs of reinnervation of target sites and the onset
of functional responses, due to the formation of functional end-organs such
as Meissner corpuscles and neuromuscular junctions, this interval also being
similar for different nerve fiber types. Our data correspond well with these
findings, since the distance that the regenerating nerve had to span was 7.5
cm, which would take about 27 days.This indicates that the sensory abnor-
malities we observed in animals with a crush lesion occur after regeneration
of the sciatic nerve and re-establishment of a functional contact between the
periphery and the central nervous system. Although few studies have
demonstrated nociceptive behavior after a crush injury12-14, the disorders they
described are moderate and short-lasting, and occurred within the first week
after lesioning of the nerve. A possible explanation for this might be an
incomplete lesion of the sciatic nerve, thus still allowing stimuli applied to
the nerves peripheral territory being perceived by the animal. In contrast, we
show that only late after crush, animals develop severe and long-lasting allo-
dynia and hyperalgesia to cold, mechanical and chemical stimuli. A recent
study by Bester et al.27 reports similar pain-related behaviors late after crush.
Here we compare the time course and magnitude of these sensory abnor-
malities to those observed in a generally accepted model for neuropathic
pain, the chronic constriction injury of the sciatic nerve1.
Immediately after surgery, the magnitude of motor function loss was com-
parable in crush and CCI animals as demonstrated by similar SFI and toe
spreading scores (testing for open field locomotor behaviour was started only
Chapter 2
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at postoperative day 7). In contrast to the crush animals, in CCI animals signs
of allodynia and hyperalgesia were already present at this time, consistent
with previous reports1,28. These responses are mediated through surviving
fibers, that are predominantly of the unmyelinated and small myelinated
class29,30.
To date, many neurobiological mechanisms which may contribute to the
pathogenesis of neuropathic pain have been identified, including changes in
both the peripheral and central nervous system3,31,32. One of the pathological
changes following nerve injury is an alteration in the level of several neu-
ropeptide genes and their products involved in pain processing. These
changes include increases in the level of galanin (GAL), vasoactive intestinal
polypeptide (VIP) and neuropeptide Y (NPY), and decreases in substance P
(sP) and calcitonin gene-related peptide (CGRP) levels in DRG neurons33,34.
Many of these plastic changes, which can contribute to to the altered senso-
ry processing present in neuropathic pain, also occur following nerve crush,
such as increased NPY,VIP and GAL and decreased sP levels35.There is also
a considerable degree of reorganization of synaptic connectivity in response
to nerve injury. Sprouting of large myelinated fibers into lamina II of the
dorsal horn, an area that normally receives only small fiber input, has been
described both in sciatic nerve crush36 and chronic constriction injury37, and
has been suggested to be play a role in the mechanical allodynia that is pres-
ent in neuropathic pain. Also, both in complete and partial nerve injuries,
sympathetic postganglionic fibers start to sprout into the DRG38,39. These
sprouted neurones form synaptic varicosities within the DRG40 and could
form an anatomical basis for a sympathetic dependency of neuropathic
pain40,41.Thus similar phenomena, contributing to the pathogenesis of neu-
ropathic pain, occur with both lesion types.
Moreover, as has been suggested for the CCI model, the development of
increased nociception is related to the preferential loss of large-diameter
myelinated fibers, thus resulting in a loss of inhibitory control30,42,43. After a
crush lesion, the myelin sheath of regenerating nerve fibers is thinner than
in an unlesioned nerve up to 12 months after lesioning7,44.Also, both senso-
ry and motor nerve conduction velocities remain decreased for over 6
months after crush25. Functionally, as in the CCI model, these phenomena
would result in a diminished large-diameter fiber mediated inhibition. On
CCI and crush injury
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the other hand, the increased sensitivity after a crush injury might also be in
part explained by hyper-responsiveness of regenerated afferent fibers, as sug-
gested by Andrew and Greenspan45.
In the experiments described here, mechanical allodynia was assessed by von
Frey probing of the mid-plantar region and chemical hyperalgesia was meas-
ured by applying mustardoil to the lateral dorsum of the hindpaw, both areas
normally innervated by the sciatic nerve. In contrast, cold allodynia was
quantified by measuring the withdrawal latencies to thermal stimulation
upon immersion of the whole hind-paw in a 4.5 °C waterbath. In this way
the exact nociceptive territory could not be determined, since the sensory
innervation from the hind paw is provided by both the sciatic and the saphe-
nous nerve.Thus we cannot rule out the possibility that the saphenous nerve
is involved in mediating this cold allodynia, consistent with a previously sug-
gested role for the saphenous nerve in pain-related disorders following sci-
atic nerve injury13,46,47. This is however not likely, since Kaupilla and Xu48
found no saphenous nerve mediated cold hypersensitivity following sciatic
nerve section. Kingery et al.12 reported a temporal correspondence between
recovery of motor function after a crush lesion and resolution of saphenous
nerve-mediated heat and pressure hyperalgesia. However, in this present
study the sensory abnormalities only occurred when the different locomo-
tor function tests returned to normal, suggesting that these altered respons-
es are mediated by sciatic reinnervation rather than through the adjacent
saphenous nerve. Since Kingery and colleagues used larger rats and a differ-
ent method to determine sciatic motor function it is difficult to compare
their time course for sciatic nerve regeneration with our present data.
Moreover, they focussed on saphenous nerve mediated hypersensitivity in
the period preceding sciatic motor function recovery, thus making it possi-
ble that later sciatic nerve mediated sensory abnormalities remained undis-
closed.
At present, the sciatic nerve crush is an animal model often used to study
nerve regeneration. A consequence of the development of hyperalgesia and
allodynia with this type of lesion might be a disturbance of the outcome of
functional and sensory recovery tests. Moreover, we have recently demon-
strated that melanocortins, often used in regeneration studies because of their
positive effects on functional recovery49-51, can worsen neuropathic pain52,53.
Chapter 2
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Therefore, in interpreting results of these studies one should bear in mind
the presence of possible confounding factors in sensory recovery, such as an
increased response to a normally non-noxious stimulus. However, this does
not hold true for the beneficial effects of melanocortins on locomotor
recovery after sciatic nerve crush.
Next to the CCI model we used here, several other experimental animal
models are available to study the mechanisms underlying the symptomatol-
ogy and possible therapeutic strategies of neuropathic pain. They include
partial tight ligation of the sciatic nerve54 and segmental spinal nerve liga-
tion55.Although the main symptoms produced by these three models  (allo-
dynia and hyperalgesia to heat, cold, and mechanical stimuli) share a high
degree of similarity, there are also substantial differences, such as the extent
and time course of the abnormalities and the response to sympathectomy41.
In the present study the sensory abnormalities in CCI and crush rats are of
comparable magnitude but greatly differ in their time course. In the clinical
situation there is a complex relationship between the aetiology, mechanisms
and symptoms of the neuropathic pain syndrome31, and possibly the differ-
ent rodent models demonstrating contrasting features involve different
pathophysiological mechanisms56 and might represent different populations
of human neuropathic pain41.
Since it is not likely that a single animal model will cover the complete range
of possible mechanisms, it is valuable to study additional animal models pro-
ducing symptoms of neuropathic pain, such as the sciatic nerve crush model
we present here, since this might provide further insight into human neuro-
pathic pain.
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Abstract
A characteristic symptom of neuropathic pain is mechanical allodynia. In animal models of
neuropathic pain, mechanical allodynia is often assessed by using von Frey filaments.
Although the forces applied with these filaments are highly reproducible, there are various
disadvantages with this method.Testing paradigms and definitions of withdrawal threshold
are not standardised. Moreover, measurements may be influenced by various conditions,
such as ambient temperature, humidity, weight bearing of the limb and stress. We have
therefore investigated another technique to assess mechanical allodynia, the “CatWalk”
automated quantitative gait analysis. With this computer-assisted method of locomotor
analysis it is possible to objectively and rapidly quantify several gait parameters, including
duration of different phases of the step cycle and pressure applied during locomotion.We
tested rats with a chronic constriction injury of the sciatic nerve, a model of neuropathic
pain, both with von Frey filaments and the CatWalk method. We demonstrate that these
rats minimise contact with the affected paw during locomotion, as demonstrated by a
reduction in stance phase and pressure applied during stance. Moreover, these parameters
show a high degree of correlation with mechanical withdrawal thresholds as determined
by von Frey filaments. We therefore suggest that the CatWalk method might serve as an
additional tool in the investigation of mechanical allodynia.
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Introduction
Neuropathic pain is a condition caused by a lesion to the peripheral or cen-
tral nervous system. Clinically it is characterized by the presence of sponta-
neous as well as different types of evoked pain.The latter include exaggerat-
ed responses to both noxious and non-noxious stimuli, referred to as hyper-
algesia and allodynia, respectively. Allodynia to tactile stimuli is a common
symptom1,2, and amongst the most problematic clinical phenomenon, since
physical contact with the environment is difficult to avoid. To study the
pathophysiological mechanisms underlying neuropathic pain symptoms such
as allodynia, several animal models of neuropathic pain have been developed
in the past decades.The most widely used models are the chronic constric-
tion injury (CCI)3, partial ligation of the sciatic nerve4 and  tight ligation of
the L5 and L6 spinal nerves5. Although there are differences between these
models, they all produce behavioural signs of neuropathic pain, including
mechanical allodynia6.
To date, the most commonly used method to assess mechanical allodynia in
such animal models is application of a series of von Frey filaments (also
known as Semmes-Weinstein filaments) to the paw.The animal’s response to
these filaments is used to determine mechanical withdrawal thresholds.
Usually, a paw withdrawal upon probing or immediately upon release of the
filament is considered a positive response2. However, responses are not always
clear-cut and their interpretation may vary between investigators. Most
commonly, the filaments are applied to the plantar surface of the hind paw
while the animal is standing on a metal grid floor, but also probing of the
lateral or dorsal surface of the paw has been performed7.Also, various para-
digms to determine withdrawal thresholds have been employed. In a fre-
quently used testing paradigm filaments are applied according to the up-and-
down method described by Dixon8. Here probing is initiated with a filament
in the middle of the series, and depending on the presence or absence of a
positive response the next smaller or larger filament is tested, respectively.
From the resulting pattern of positive and negative responses a 50% with-
drawal threshold can be calculated2. Alternatively, filaments can be used in
order of increasing stiffness, starting with the smallest filament.With this test-
ing in ascending order, each filament can be applied a different number of
CatWalk and von Frey
59
proefschrift dorien  30-01-2003  17:42  Pagina 59
times, at various intervals, and held in position for different periods.Also, dif-
ferent definitions of withdrawal threshold have been employed; for example
the smallest filament eliciting at least one positive response9, or three out of
three10, three out of five7, or four to six out of ten positive responses11.Yet
another way to quantify mechanical allodynia is by testing either a complete
series of filaments, or a selection of two, and calculating the total number of
responses as a percentage of total number of applications2,6. Thus, by using
von Frey probes, assesment of mechanical allodynia can be performed in
numerous ways, and may be influenced by subjectivity, thus making it diffi-
cult to compare results obtained from different studies.
In the present study we investigated whether mechanical allodynia can also
be measured in a more objective way.We produced a mechanical allodynia
by subjecting rats to a chronic constriction injury of the sciatic nerve. It is
to be expected that an increased sensitivity to mechanical stimuli will cause
the animal to exert less pressure on the affected limb during walking, and
will minimize contact of this paw with the floor.We tested CCI rats on the
“CatWalk”, an automated quantitative gait analysis method recently devel-
oped in our laboratory
12
. Here we compare von Frey withdrawal thresholds
in these animals with relevant data obtained from the CatWalk analysis.
Materials and methods
Animals and surgery
All procedures in this study were performed according to the Ethical
Guidelines of the International Association for the Study of Pain
13
and
approved of by the Ethics Committee on Animal Experiments of Utrecht
University.
Twelve male Wistar rats weighing 250-300 g at the start of the study were
used.Animals were housed in groups of 2-3 in plastic cages on sawdust bed-
ding. They were kept at a 12/12hr light/dark cycle, with food and water
available ad libitum.
Animals were anaesthetised with a single subcutaneous injection of
Hypnorm (Duphar, the Netherlands) diluted in saline (1:2, 0.3 ml/100 g
bodyweight).
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Four loose ligatures were placed around the right sciatic nerve as described
previously
3
. Subsequently the incision was closed with silk sutures and the
animals were allowed to recover for a 2-3 day period.
Since we previously observed that sham-surgery does not induce any
changes in  withdrawal thresholds to von Frey stimulation or locomotor
function (unpublished results, see also Kupers et al.
14
,Vrinten et al.
15
), in this
experiment we used only CCI animals.
Test procedures
Before surgery and at 2, 5, 8 and 10 weeks after surgery, the following tests
were performed:
1 Mechanical withdrawal thresholds (von Frey) 
Paw withdrawal threshold in response to a mechanical stimulus was deter-
mined using a series of von Frey filaments (Stoelting,Wood Dale, IL), rang-
ing from 1.08 to 21.09 g.Animals were placed in a plastic cage with a metal
mesh floor, allowing them to move freely. They were acclimatised to this
environment for approximately 10 minutes prior to testing, to allow for
behavioural accomodation. Von Frey filaments were applied to the mid-
plantar surface of the operated hind paw through the mesh floor. Probing
was only performed when the animals paw was in contact with the floor.
Each probe was applied to the foot until it just bent, and kept in this posi-
tion for 6-8 s
2
. Interval between consecutive filaments was at least 5 s.
Filaments were applied in ascending order, and the smallest filament that
elicited a foot withdrawal response was considered the threshold stimulus.
2  “CatWalk” automated gait analysis
The animals traverse a walkway (plexiglass walls, spaced 8 cm apart) with a
glass floor (100 X 15 x 0.6 cm) located in a darkened room. Light from an
otherwise completely encased white fluorescent tube (length 110 cm, 30W)
enters the distal (from the observer) long edge of this glass floor. Sufficiently
far from the edge it strikes the surface below the critical angle and is entire-
ly internally reflected. Only at those points where a paw touches the glass,
light exits the floor and scatters at the paw, illuminating the points of con-
tact only (fig. 1A).Via a mirror, the corridor’s floor is monitored by a Pulnix
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TM-765E CCD camera (Pulnix Inc., UK) equipped with a wide angle
objective (Cosimar 8.5mm) (fig. 1B).The intensity of the signal depends on
the degree of paw floor contact and increases with pressure applied
16
. The
camera detects the average intensity within a rectangular area (pixel) in
which total skin-floor contact may differ.The more pressure is exerted, the
larger the total area of skin-floor contact and thus the brighter the pixel (fig.
1C).
The signal is digitized by a PCImage-SG frame grabber board (Matrix Vision
GmbH, Oppenheimer, Germany). The CatWalk program  acquires, com-
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Figure 1.
Priciple of the CatWalk setup 
(A) Light from a fluorescent bulb is sent through a glass plane. Light rays are completely reflected
internally, except where a paw is placed on the glass surface.This results in a sharp image of the paw.
(B) Images are reflected by a mirror placed at a 45º angle, and recorded by a CCD videocamera
connected to a computer. (C) Example of a paw print during walkway crossing.The footpad and toes
are clearly visible. For visualisation purposes, intensity is inverted, i.e. the darker the print on this fig-
ure, the brighter it appeared on the walkway. Influence of skin-floor contact on pixel intensity in two
neighbouring pixels is shown (insets). For details see text. (D) A faint image of the rats body is visi-
ble over the paw prints, thus making it possible to identify the different paws (adapted from Hamers
et al.12).
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presses, stores and eventually analyzes the “videotapes” of animals crossing
the walkway.All areas containing pixels brighter than a preset threshold value
are also stored uncompressed, in order to circumvent compression related
artefacts in the eventual analysis. Note that a very faint image of the animal
crossing the walkway is present, unless all background illumination is elimi-
nated completely (fig. 1D). However, this image is so faint in comparison
with paw prints that it does not interfere with the measurement. In effect,
without the shape of the animal moving through the corridor interactive
labeling of prints is far more difficult.
Data analysis is performed by first (automatically) labeling all areas contain-
ing one or more pixels above a certain analysis threshold. In a second inter-
active pass these areas are assigned to one of the paws; user intervention is in
most cases only required at initial contact of each paw, enabling analysis of a
few seconds of walkway crossing within less than a minute. Ordered data are
eventually output in ASCII-format which is human readable and which can
be used as input of almost every spreadsheet program.
Animals are not pre-trained to cross the walkway as the Wistar rats used in
our laboratory have no hesitation in crossing the walkway spontaneously
with sufficient speed. A typical crossing contains 6 step cycles and averaged
data from all step cycles in a crossing are used in the analysis.
Analysis of these recordings yields many parameters
12
of which the follow-
ing are of most interest in the CCI model:
step sequences (see Table 1) with their respective frequencies;
regularity index (RI); a measure of interlimb coordination. Interlimb
coordination is complete if only normal step sequences are used during
uninterrupted locomotion.The RI grades the degree of interlimb coordina-
tion as follows: RI = (NSSP * 4 / PP) * 100(%) wherein NSSP represents
the number of normal step sequence patterns and PP the total number of
paw placements. Both extra paw placements and loss of certain paw place-
ments (irregular walking on 3 paws) will decrease RI;
intensity; a measure for the mean pressure exerted by the paw during floor
contact;
duration of stance phase; and
duration of swing phase.
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Since the absolut duration of stance or swing phase depends on the animals
walking speed, these parameters are transformed to a fraction of total step
duration according to the following formula:
fraction stance or swing phase = stance or swing phase / (stance phase +
swing phase)
Data analysis and statistics
For each animal, stance or swing phase,mean intensity during stance and von
Frey withdrawal thresholds are calculated as a percentage of respective pre-
operative values. As such each animal serves as its own control. Von Frey
withdrawal thresholds are transformed logarithmically, in order to obtain a
linear scale of increasing intensities with increasing filament size. Data from
stance or swing phase and mean intensity are represented as mean ± standard
error of the mean (s.e.m.). Because of the discrete nature of the von Frey
data, these are represented as median and 25th-75th percentiles.
To compare differences in stance phase and mean intensity at different time
points, ANOVA’s were performed, followed by paired samples T-tests (com-
parisons with pre-operative values). Von Frey data were analysed using a
Kruskal-Wallis test, followed by Mann-Whitney U tests. Bonferroni correc-
tions were performed.
To analyse correlations between von Frey withdrawal thresholds and mean
intensities, stance or swing phase, Pearsons correlation coefficients were calcu-
lated. Data are presented as X-Y scatter plots with either % change in mean
intensity, stance or swing phase on the Y-axis and corresponding von Frey
thresholds on the X-axis. Regression lines were also calculated and plotted.A
probability level of 0.05 was considered significant.
Results
Mechanical withdrawal thresholds (von Frey)
With preoperative testing, none of the animals responded to the largest von Frey
filament tested (21.1 g), on either of the hindpaws.After chronic constriction of
the sciatic nerve mechanical allodynia developed, as demonstrated by a large
decrease in withdrawal threshold of the operated hind paw at 2 weeks postoper-
Chapter 3
64
proefschrift dorien  30-01-2003  17:42  Pagina 64
ative, to 31.0 (31.0-46.0) % of preoperative thresholds (median and 25th-75 th
percentiles).
Thereafter thresholds gradually increased to 100 (84.8-100) % of preoperative
thresholds at 10 weeks postoperatively,which is not significant from baseline (fig.
2).Withdrawal thresholds at the contralateral (non-lesioned) side remained con-
stant throughout the experiment..
“CatWalk” analysis
1 General walking pattern
Before surgery the predominant step pattern is alternate (forelimb and contralat-
eral hindlimb in sequence).After placement of the ligatures this remains the main
step pattern,although other patterns also occur (cruciate or rotary; for description
of step patterns, see Table 1). Regardless of these changes in step patterns, the
Regularity Index remains constant, indicating that there is no significant loss of
interlimb coordination in CCI animals.Thus placement of the lesioned paw, no
matter how short, is present in almost all step cycles at all time points used.
CatWalk and von Frey
65
Figure 2.
Time course of different parameters obtained in rats with a chronic constriction injury (CCI).
Measurements were taken preoperatively (t = 0), and at 2, 5, 8 and 10 weeks after CCI. Mechanical
withdrawal thresholds as determined by application of von Frey filaments, mean intensity during
stance, as a measure of paw pressure, and duration of stance and swing phase are plotted as per-
centages of respective preoperative values. Data on intensity, stance and swing phase are obtained
by the CatWalk method. Data are presented as mean ± s.e.m. (mean intensity and stance phase) or
median and 25th-75th percentile (von Frey) of 12 rats. (* p < 0.05 compared to baseline)
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2 Intensity of the right hind limb 
Data analysis was performed with a threshold value of 40 (arbitrary units,
a.u., possible range 0-255), i.e. all pixels brigher than 40 are used.The mean
intensity with which the paw is placed is computed over the whole stance
period. Mean baseline intensity of the right hind limb was 86.6 ± 3.2 (mean
± s.e.m.) (a.u.).Two weeks after placement of the ligatures, intensity was sig-
nificantly reduced to 79.6 ± 3.6 % of preoperative value (p<0.05) and there-
after gradually normalized to 100.3 ± 3.4 % (not significant) at ten weeks
postoperatively (fig. 2).
When these % changes in mean intensities were plotted against % changes
in von Frey thresholds, there was a very high degree of correlation between
these two parameters (Pearsons = 0.63, p < 0.001) (fig. 3A).
There was no consistent change in mean intensities at the contralateral side,
indicating that  pressure of the contralateral hindpaw does not change. Since
von Frey thresholds remained constant in this paw, correlations could not be
calculated.
3 Duration of stance and swing phase of the right hind limb
Preoperatively, duration of the stance phase was 0.71 ± 0.02 (fraction of
total step duration).Two weeks after surgery the time that the lesioned paw
was in contact with the floor was significantly reduced to 51.9 ± 4.4% of
preoperative values (p < 0.05). In the following weeks this gradually increased
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Table 1. Limb sequences in regular stap patternsa
a RF: right forelimb, RH: right hindlimb,
LF: left forlimb, LH: left hindlimb (adapt-
ed from Cheng et al.28)
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to 83.6 ±7.5 % (not significant from preoperative values) (see figure 2).There
was also a very high degree of correlation between this parameter and von Frey
withdrawal thresholds, as demonstrated in fig. 3B (Pearsons = 0.67, p < 0.001).
Initial swing phase duration was a fraction of 0.29 ± 0.02 of total step dura-
tion.At two weeks postoperative this increased to 233.7 ± 19.9 % of preoper-
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Figure 3.
Correlation between mean intensi-
ty during stance (A), stance phase
duration (B), swing phase duration
(C)  and von Frey withdrawal
thresholds in CCI rats. Data are
presented as mean ± s.e.m. Linear
regression lines are plotted.
Pearson correlation coefficients
(pcc) are calculated over 62 indi-
vidual datapoints (** p < 0.001).
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ative value, (p < 0.05). At ten weeks postoperative swing phase was again
decreased to 151.8 ± 20.1 %, (not significant, see figure 2). Correlation
between swing phase and von Frey thresholds was again very high (Pearsons
= -0.61, p < 0.001 , see figure 3C).¸ 
There was no significant change in duration of stance or swing phase in the
contralateral paw. As with the mean intensities, correlations with von Frey
thresholds could not be calculated.
Discussion
In this paper we describe a possible novel approach to quantify mechanical allo-
dynia in a rat model for neuropathic pain. We found a strong correlation
between von Frey mechanical withdrawal thresholds and parameters obtained
from CatWalk gait analysis.
Currently, von Frey probing is one of the most frequently used methods to
measure mechanical allodynia in various animal models.Although the applica-
tion forces of the von Frey filaments have been shown to be objective and repro-
ducible
17
there are various setbacks. One of the problems is that there are many
different ways to assess and define mechanical withdrawal thresholds using von
Frey probing.Moreover, bending forces of the filaments are influenced by ambi-
ent humidity and, to a lesser extent, temperature. Finally, filaments may wear off
with extensive use
18,19
. Since testing is usually done in non-restrained animals, the
experimenter has to wait for the animal to hold its paw in the right position,
which then should remain the same, as weight bearing of the limb might be a
confounding factor in determining von Frey withdrawal thresholds
10
. In order to
determine thresholds, multiple filaments have to be applied, which also takes
time. Moreover, repetitive testing with short intervals may bias mechanical
threshold determinations
2
and possibly disclose wind-up like pains
20
.
The CatWalk method for automated gait analysis we used here allows for inves-
tigation of various walking parameters within a single run. Measurements are
performed in freely moving, non-restrained animals,with minimal intervention,
thus reducing the potentially confounding effects of stress
7
. Since the time need-
ed for an animal to cross the walkway is in the order of several seconds it is a
very rapid method, allowing relatively large groups of animals to be tested in a
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short time span. Moreover, data acquisition is performed by computer which
allows analysis of several parameters simultaneously. In the present study we
looked at changes in mean signal intensity and the duration of different phases
of a complete step cycle in rats with a chronic constriction injury (CCI).We
hypothesized that these parameters would be affected as a result of the increased
sensitivity to mechanical stimulation in these rats.
The mean signal intensity during placement of the paw when crossing the
CatWalk walkway is an estimate of paw pressure, since signal intensity decreases
when less pressure is applied with the paw
16
.There was a high degree of corre-
lation between intensity measurements and von Frey withdrawal thresholds of
the experimental hind paw.This suggests that lowered mechanical withdrawal
thresholds, indicative of mechanical allodynia, are paralleled by decreased pres-
sure applied with the paw during walking. In mice subjected to sciatic nerve
crush, an injury also associated with neuropathic pain
21
, we also observed this
decrease in applied pressure during locomotion by using CatWalk analysis
(unpublished results) .These observations are in agreement with earlier studies
reporting a decrease in standing weight bearing of the affected limb associated
with mechanical allodynia in different pain models, such as bone cancer pain
22
,
carrageenan-induced inflammation
23
and urate arthritis
24
.Also, in arthritic rats, a
decrease in weight load during locomotion was observed, presumably reflecting
pain
24,25
.
Duration of stance and swing phase in these CCI rats were decreased and
increased, respectively, and these parameters also demonstrate a high degree of
correlation with von Frey thresholds. The obervation that in a rat model of
inflammatory pain, i.e. carrageenan injections in the ankle joint, stance phase
duration was also decreased  (Angeby-Möller, personal communication) sup-
ports our findings.The use of other neuropathic or inflammatory pain models
displaying mechanical allodynia
4,5,26
might further confirm this.
Together, our data imply that the CCI rats minimize contact with floor during
walking, as demonstrated by an increased swing phase and shorter stance phase
of the neuropathic hind paw and a decrease in pressure applied during this stance
phase. Moreover, the time courses of these changes in intensity and step phases
are similar to that of the von Frey withdrawal thresholds, indicating that these
CatWalk parameters parallel variations in mechanical allodynia  in these rats.
Since increased mechanocsensitivity might be parallelled by an increase in
CatWalk and von Frey
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touch-evoked responses of spinal α-motorneurones
27
, it is possible that the
observed changes in gait reflect changes in motorneuron activity, rather than
direct responses induced by physical contact with the floor. In this way, alter-
ations in intensities and stance phase might represent an indirect measure of allo-
dynia. However, since these parameters correlate very well with the response
evoked by direct application of von Frey filaments, we suggest that the CatWalk
method might serve as an alternative tool to assess mechanical allodynia in CCI
rats.Although we have not performed any pharmacological interventions in the
present study, it is very likely that future studies will reveal pharmacological sen-
sitivity of the CatWalk method, considering the high degree of correlation
between von Frey probing and this method.
A possible drawback of the CatWalk method is that it appears to be less sensi-
tive than von Frey probing. At 8 weeks postoperative, von Frey values are sig-
nificantly different from preoperative, wherease CatWalk parameters do not
reach significance (see figure 2).The magnitude of changes between pre- and
postoperative intensities and stance phase durations was smaller than those of
von Frey thresholds.However, the increase in swing phase duration is much larg-
er. Moreover, at ten weeks postoperative this parameter is still increased (over
150% of preoperative, although not significant), whereas von Frey thresholds at
this time point have completely normalised. This suggests that the CatWalk
method might detect small changes in mechanical sensitivity that are not detect-
ed by von Frey probing. Furthermore, the CatWalk method has several advan-
tages over the von Frey method, such as the convenience and objectivity of data
collection, and the possibility to store and review the images of rats crossing the
walkway.
In summary, the CatWalk method allows for rapid and objective analysis of
many locomotor parameters. In CCI rats, displaying mechanical allodynia, we
demonstrated that measurements of paw pressure and duration of stance and
swing phase obtained with the CatWalk method show a high degree of corre-
lation with mechanical withdrawal thresholds as determined by application of
von Frey filaments.This suggests that the CatWalk method might provide an
alternative means to quantify mechanical allodynia. Moreover, since the
CatWalk method is not limited to rats, it might become a practical tool to study
mechanical allodynia in other animal models, in which von Frey probing can be
more difficult.
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Abstract
The presence of both pro-opiomelanocortin derived peptides and melanocortin (MC)
receptors in nociception-associated areas in the spinal cord suggests that, at the spinal level,
the MC-system might be involved in nociceptive transmission. In the present study we
demonstrate that a chronic constriction injury (CCI) to the rat sciatic nerve, a lesion that
produces neuropathic pain, results in changes in the spinal cord MC system, as shown by
an increased binding of 
125
I-NDP-MSH to the dorsal horn. Furthermore, we investigated
whether intrathecal administration (in the cisterna magna) of selective MC receptor ligands
can affect the mechanical and cold allodynia associated with the CCI. Mechanical and cold
allodynia were assessed by measuring withdrawal responses of the affected limb to von
Frey filaments and withdrawal latencies upon immersion in a 4.5°C waterbath, respective-
ly. We show that treatment with the MC receptor antagonist SHU9119 has a profound
anti-allodynic effect, suggesting that the endogenous MC system has a tonic effect on noci-
ception. In contrast, administration of the MC4 receptor agonists MTII and D-Tyr-MTII
largely increases the sensitivity to mechanical and cold stimulation. No antinociceptive
action was observed after administration of the selective MC3 receptor agonist Nle-g-
MSH.Together, our data suggest that the spinal cord MC-system is involved in neuropath-
ic pain and that the effects of MC receptor ligands on the responses to painful stimuli are
exerted through the MC4 receptor. In conclusion, antagonism of the spinal melanocortin
system might provide a new approach in the treatment of neuropathic pain.
Chapter 4
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Introduction
In humans, damage to the nervous system - a peripheral nerve, dorsal root
ganglion, dorsal root or the central nervous system - can lead to a pain state
referred to as neuropathic pain. This syndrome is characterised by sponta-
neous pain in combination with allodynia (pain evoked by normally non-
painful stimuli) and hyperalgesia (an increased response to painful stimuli). In
current clinical practice, several drugs are used to control neuropathic pain,
including tricyclic antidepressants (for review see Ollat and Cesaro
1
,
Kingery
2
), anticonvulsants
3
, systemic administration of local anesthetics
4,5
and
NMDA receptor antagonists
6,7
. In spite of this wide range of drugs, the treat-
ment of neuropathic pain is often unsatisfactory and limited by the occur-
rence of adverse side-effects.
Over the past decade a number of animal models of neuropathic pain have
become available, producing symptoms that closely resemble those observed
in human neuropathic pain. Research using these preclinical models has
yielded an array of potential new analgesics, including different enzyme
inhibitors, ion channel blockers and ligands for various receptors (for review,
see Chizh et al.
8
,Yaksh
9
).Another potential target in the control of pain that
has received very little attention is the melanocortin system. It has been pre-
viously reported that central administration of the melanocortins ACTH
(adrenocorticotropic hormone) and α-MSH (α-melanocyte stimulating
hormone) causes hyperalgesia in various pain tests
10-12
. Furthermore, these
peptides have also been shown to antagonize the analgesic effects of mor-
phine and β-endorphin13-15. The mechanisms through which these effects
were exerted, however, remained unclear since no receptors for these pep-
tides were identified. Only in recent years, 5 melanocortin (MC) receptors
subtypes have been identified (for review, see Cone et al.
16
,Tatro
17
), of which
the MC3 and MC4 receptor are expressed in the nervous system. Compared
to the MC3 receptor, the MC4 receptor has a much more widespread dis-
tribution throughout the brain. Moreover, it is the only subtype of which
expression has been demonstrated in the spinal cord
18
. Binding of 
125
I-NDP-
MSH, a synthetic α-MSH analogue, to rat spinal cord demonstrated that the
most abundant MC receptor expression is present in the superficial dorsal
horn (lamina I and II) and in the grey matter surrounding the central canal
Melanocortins in neuropathic pain
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(lamina X), areas that are important in nociceptive transmission
19
.
Furthermore, POMC mRNA was also demonstrated in spinal cord
19
, and
immunoreactivity for the POMC-derived peptides β-endorphin, ACTH
and α-MSH has been described in the dorsal horn and lamina X
20,21
.
Together, these findings suggest the presence of a functional MC-system in
the rat spinal cord. Considering the localization of 
125
I-NDP-MSH binding
in nociception-associated areas in the spinal cord, and the fact that the MC4
receptor is the only MC receptor subtype for which mRNA has been
detected in the spinal cord, the spinal MC4 receptor might be a potential
target in the ongoing search for new analgesics.
As recently selective ligands for the MC receptors became available, it is now
possible to study a putative role for the MC4 receptor in the control of neu-
ropathic pain. The aim of the present study was to investigate whether
changes in the spinal cord MC-system play a role in neuropathic pain.
Therefore in situ binding of 
125
I-NDP-MSH to rat lumbar spinal cord sec-
tions was quantified. The chronic constriction injury (CCI)
22
was chosen
because of its wide acceptance as a reliable and reproducible model for neu-
ropathic pain. In addition, we investigated whether selective MC receptor
ligands can alter the response of control and mononeuropathic rats to painful
stimuli.
We demonstrate that a CCI results in an increase in 
125
I-NDP-MSH bind-
ing to the spinal cord, suggesting an increase in MC receptor levels.We also
show that in CCI rats intrathecal administration of the MC receptor antag-
onist SHU9119 induced a decreased sensitivity to cold and mechanical stim-
ulation, whereas the strong MC receptor agonist MTII or the more selective
MC4 receptor agonist D-Tyr MTII had the opposite effect. In contrast, in
control rats these ligands had no effect on sensitivity. Furthermore we show
that treatment with the selective MC3-R agonist Nle-γ-MSH had no effect
on sensitivity.
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Table 1.
Affinity (Ki) and potency (EC50) of melanocortin receptor ligands for the rat MC3 and MC4
receptor
Affinities and potencies are determined on HEK 293 cells expressing either the rat MC3 or rat
MC4 receptor, using 125I-NDP-MSH as radioligand (for Ki) or the LacZ reporter gene (for EC50).
Data are expressed as mean ± 95% confidence interval (adapted from Adan et al.38)
Materials and Methods
Peptides
For in vivo administration MTII (Melanotan-II or cyclo-[Nle4, Asp5, D-
Phe7, Lys10]α-MSH-(4-10)), SHU9119 (cyclo-[Nle4, Asp5, D-Nal(2)7,
Lys10]α-MSH-(4-10)), D-Tyr-MTII (cyclo-[Nle4, Asp5, D-Tyr7, Lys10]α-
MSH-(4-10)) and Nle-γ-MSH (Ac-[Nle3]-γ2-MSH-NH2) were used.
MTII  was purchased from Bachem Feinchemicalien (Buberdorf,
Switzerland), SHU9119, Nle-γ-MSH and D-Tyr-MTII were synthesized
using Fmoc solid phase synthesis as reported elsewhere
23
. Peptides were puri-
fied using reversed phase preparative HPLC (high-pressure liquid chro-
matography) to a purity of ± 90%, estimated after analysis by analytical
HPLC at 215 nm. Molecular weight was confirmed by mass spectrometry
performed on a Micromass Quattro sq. Potencies and affinities of these four
peptides for the rat MC3 and MC4 receptor are shown in table 1.
For in situ melanocortin binding to spinal cord cryosections 
125
I-NDP-MSH
was used. NDP-MSH (Melanotan-I or [Nle4, D-Phe7]α-MSH) was pur-
chased from Bachem Feinchemicalien (Buberdorf, Switzerland) and iodinat-
ed using bovine lacto-peroxidase (Calbiochem) and 
125
I-Na (ICN) as
described elsewhere
24
, followed by HPLC-purification on a C18 column
(µBondapak 3.9 x 300 mm,Waters).
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Animals
59 Male Wistar rats weighing 200-240 g at the start of the study were used.
Animals were housed in groups of 2-3 in plastic cages on a sawdust bedding.
They were kept at a 12/12hr light/dark cycle, with food and water available
ad libitum. All testing procedures in this study were performed according to
the Ethical Guidelines of the International Association for the Study of
Pain
25
and approved of by the Ethics Committee on Animal Experiments of
the Utrecht University.
Surgery
Animals were anesthetized with a single subcutaneous injection of Hypnorm
(Janssen Pharmaceutical LTD., Grove, Oxford) containing 0.315 mg/ml fen-
tanyl citrate and 10 mg/ml fluanisone, at a dose of 0.3 ml/kg bodyweight.
In 33 animals the right sciatic nerve was exposed at mid-thigh level by blunt
dissection and a CCI was made by placing 4 loose ligatures of 4-0 chromic
catgut (Ethicon INC., Norderstedt) around the nerve, as previously
described by Bennett and Xie22. In 4 animals the same procedure was per-
formed except for placement of the ligatures (sham surgery). After this the
incision was closed with silk sutures and the animals were allowed to recov-
er.The remaining 22 animals only received a cisterna magna cannula (con-
trol animals).
Placement of the cannulae was performed 2 weeks after the sham or CCI
lesion. Rats were again anesthetized and placed in a stereotactic frame.The
skull was exposed by a midline incision.A steel cisterna magna cannula was
inserted through a burr hole just before the squama occipitalis and two small
screws were placed lateral to the midline for extra fixation. Cannula and
screws were fastened with dental acrylic.The animals were allowed a four-
day recovery period before testing was initiated.
In situ 125I-NDP-MSH binding to spinal cord
Seven animals that remained naive to treatment (4 sham and 3 CCI animals)
were used for in situ
125
I-NDP-MSH binding.
Tissue preparation: Four weeks after placement of the ligatures or sham sur-
gery the rats were sacrificed by decapitation.The lumbar spinal cord was rap-
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idly removed and frozen by submersion in 2-methyl-butane (Fluka
Chemika, Buchs, Switzerland) on dry ice. Spinal cords were stored at –80 °C
until further processing. From lumbar segments L4 - L6 cryostat sections (16
µm) were prepared and mounted on gelatin-coated slides (2 sections from
each segment per slide).
In situ binding assay: From each animal 1 slide was incubated with 
125
I-NDP-
MSH as described previously26. In short, the sections were prewashed, incu-
bated with 
125
I-NDP-MSH (106 cpm/ml) in binding buffer for 1 hr, washed
6 times to stop binding reactions and rapid air dried.A second slide from each
animal was incubated with 
125
I-NDP-MSH in the presence of 3 µM non-iod-
inated NDP-MSH to determine the specificity of tracer binding.All binding
assays were done on the same day, in one experimental session.
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Figure 1.
125I-NDP-MSH binding to rat spinal cord sections.
A: Nissl staining of a representative spinal cord section, demonstrating the neuroanatomy. B:
Diagram representing the sampling template used for determining 125I-NDP-MSH binding in X-ray
film autoradiograms of rat spinal cord sections. a: superficial dorsal horn (left and right); b: lamina X;
c: dorsal white matter column used for determining background value. For each region the mean
value of 3 (superficial dorsal horn and background) or 4 (lamina X) samples was calculated. C,D:
X-ray film autoradiogram of 125I-NDP-MSH binding to a representative rat spinal cord section.
Sections were incubated with 125I-NDP-MSH in the absence (C) or presence (D) of 3 µM non-
iodinated NDP-MSH. Specificity of binding present in C is demonstrated by its inhibition in D.
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In order to visualize the neuroanatomy more clearly an adjacent section was
Nissl stained (fig. 1A).
Autoradiography and analysis:Autoradiography was performed by exposing
an X-ray film (BioMax MR, Kodak) directly to the slides for 1 week. All
slides were run on the same, single film, with CCI and sham samples ran-
domly divided over the film. Autoradiograms were digitized and quantita-
tively analyzed using the MCID (Microcomputer Imaging Device, Imaging
Research Inc.). For each section, binding was measured in three anatomic
regions, using a sampling template as depicted in fig. 1B.Within each region
3 or 4 samples were measured and the mean value was calculated. Specific
binding was calculated by subtraction of the mean background value, deter-
mined within the dorsal white matter column of the same section.
Absorbance values were converted into cpm using a linear calibration curve.
Drug administration
30 CCI and 22 control animals were used to study the effects of the differ-
ent peptides on nociception. Peptides were dissolved in 10 µl of saline and
injected through the cisterna magna cannula by means of a Hamilton
syringe.
On each testing day CCI rats were randomly divided into 3 groups (N =10
each), each group randomly and blindly receiving one of the following
doses: vehicle, SHU9119: 0.15, 0.5 or 1.5 µg (0.140, 0.466 or 1.40 nmol
respectively), MTII: 15, 30, 100 or 500 ng (14.6, 29.2, 97.6 or 488.2 pmol
respectively), D-Tyr-MTII: 0.3, 1.0 or 3.0 µg (0.289, 0.962 or 2.885 nmol
respectively), Nle-γ-MSH: 5 µg (3.22 nmol) or a combination of 15 ng
MTII and 0.5 µg SHU9119. Thus in total, 13 groups of 10 CCI animals
were tested.
Similarly, on each testing day control rats were randomly divided in 2 groups
(N=11 each), each group randomly and blindly receiving one of the fol-
lowing doses: vehicle, 1.5 µg SHU9119, 500 ng MTII or 3 µg D-Tyr-MTII
(corresponding to the highest doses tested in CCI animals).Thus in total 4
groups of 11 control animals were tested.
Using this experimental setup, animals received only a single injection with
a single dose on each testing day.The study was continued until all doses of
all drugs were tested.Animals were given at least two days rest between drug
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80
proefschrift dorien  30-01-2003  17:42  Pagina 80
injections to minimize any possibility of drug interactions or development
of tolerance.
Testing procedures
1 Temperature stimulation test
Withdrawal latency to a temperature stimulus was measured by immersing
the right (experimental) hind paw into a 4.5°C or 47.5°C water bath. Upon
immersion of the paw an electronic circuit including a timer was closed.
Withdrawal of the paw resulted in a discontinuation of the circuit, which
stopped the timer, thus allowing a precise registration of the withdrawal
latency time. Cut-off time for both temperatures was set at 10 s. to avoid skin
damage.
2 Mechanical stimulation test
Foot withdrawal threshold in response to a mechanical stimulus was deter-
mined using a series of von Frey filaments (Stoelting,Wood Dale, IL), rang-
ing from 1.08 to 21.09 g.Animals were placed in a plastic cage with a metal
mesh floor, allowing them to move freely.They were allowed to acclimatize
to this environment prior to the experiment.The filaments were presented
to the midplantar surface as described by
27
, starting with the smallest fila-
ment. Each probe was applied to the foot until it just bent and the smallest
filament eliciting a foot withdrawal response was considered the threshold
stimulus.
For both mechanical and temperature stimulation tests baseline values were
determined and measurements were repeated 15, 30 and 60 min after drug
or vehicle administration.
Grooming assay 
In 8 CCI animals a grooming assay was performed as described by Gispen et
al28. In short, animals were placed in a plastic observation cage immediately after
injection of 500 ng MTII (N=4) or saline (N=4) through the cisterna magna
cannula. Starting 10 minutes after injection, grooming (face washing, genital
grooming, body licking and grooming, scratching and paw licking) was scored
every 15 seconds. Observation was stopped 50 minutes after injection.
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Data analysis and statistics
All data are expressed as mean ± standard error of the mean (S.E.M) for visu-
alization purposes only.
For in situ 
125
I-NDP-MSH binding to spinal cord, the overall mean of levels
L4-L6 and 1-2 sections per rat (thus rendering one datapoint per anatomic
region per rat) were used to calculate group means and S.E.M. Differences
between sham and CCI groups were analyzed using an independent
Students T-test.
For the temperature stimulation test the difference between baseline and
post-injection withdrawal latency was calculated for each animal at each
time point.
To obtain a linear scale of perceived intensity in the mechanical stimulation
test the logarithm of the withdrawal thresholds was plotted.As for the tem-
perature stimulation test, differences between post- and pre-treatment with-
drawal thresholds were calculated.
For mechanical and temperature stimulation, differences in baseline values
between between control and CCI groups, and differences between drug
treatment groups were analyzed using the Kruskall-Wallis test because of the
non-parametric nature of the data.When appropriate, post hoc analysis was
performed using the Mann-Whitney U test, comparing each treatment dose
with vehicle, and for each treatment comparing the highest dose with the
intermediate and lowest dose, respectively.A Bonferroni-correction was per-
formed.
Where possible, dose-response curves were generated.Therefore, post-injec-
tion values  were expressed as a percentage of baseline value. Mean ± S.E.M.
of these percentages were plotted against the administered dose. Dose-
response curves are reported for  the time of peak effect (30 min post-injec-
tion for MTII and D-Tyr-MTII, and 15 min post-injection for SHU9119).
Differences in grooming scores were analyzed using an independent
Students T-test.
For all tests, a probability level of  ≤0.05 was the criterion for a significant
difference.
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Results
In situ 125I-NDP-MSH binding to spinal cord
Specificity of the 
125
I-NDP-MSH binding is indicated by its inhibition in the
presence of 3 µM NDP-MSH, which reduced binding to background level
(figs. 1C and D).
As demonstrated previously19, specific 
125
I-NDP-MSH binding was highest
in the superficial dorsal horn (corresponding to lamina I-II) and lamina X.
In CCI animals binding in lamina I-II on both the ipsi- and contralateral
side was significantly increased as compared to sham animals (125.5 % and
118.7% of sham values, respectively). In contrast, binding to lamina X did
not differ between groups (fig. 2).
Baseline values for temperature and mechanical stimulation
In control animals, the mean baseline mechanical withdrawal threshold for
all 4 groups at all time points was 21.09 ± 0 g (mean ± S.E.M.) In CCI ani-
mals the overall mean baseline was significantly lower (5.32 ± 0.21 g, rang-
Melanocortins in neuropathic pain
Figure 2.
125I-NDP-MSH binding levels in different anatomic regions in rat lumbar spinal cord (L4-L6) cryostat
sections.
Spinal cords were collected 4 weeks after CCI or sham surgery. Regions were analysed by sampling
the corresponding region of an X-ray film autoradiogram, using a template as depicted in fig. 1A.
Values were converted to cpm using a linear calibration curve. Specific binding within each region
was determined by substracting the mean background value obtained from the dorsal white matter
from the same section. For each region the overall mean of levels L4-L6 from 1 or 2 sections was
calculated per rat.
Data are represented as mean ± S.E.M. of 4 (sham) or 3 (CCI) rats (* p<0.05 vs. sham).
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ing from 4.83 ± 0.50 to 6.67 ± 1.06 g for the 13 different randomized
groups), thus indicating a mechanical allodynia.
At 4.5°C overall mean baseline withdrawal latency in control animals was
9.86 ± 0.06 s (ranging from 9.75 ± 0.19 to 10 ± 0 s). In CCI animals, mean
baseline withdrawal latency was significantly lower (6.05 ± 0.35 s, ranging
from 3.47 ± 0.41 to 7.36 ± 1.07 s), thus demonstrating a cold allodynia.
At 47.5 °C overall mean baseline withdrawal latency in control animals was
4.52 ± 0.22 s (ranging from 3.57 ± 0.26 to 5.47 ± 0.45 s).This value was
not significantly different from that in CCI animals (4.66 ± 0.22 s, ranging
from 3.47 ± 0.41 to 6.98 ± 1.26 s).These data are shown in fig. 3.
Although baseline values could differ between randomized groups there was
no correlation between these values and administration of either an agonist
or antagonist, nor were baseline values consistently changed by previous
administration of either an agonist or antagonist (data not shown).
Vehicle injection
An injection of 10 µl of saline through the cisterna magna cannula had no
effect on the responses to any of the tests performed, neither in CCI rats, nor
in control rats.
Administration of SHU9119
In CCI rats, treatment with SHU9119 (0.15, 0.5 and 1.5 µg) produced a tac-
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Figure 3.
Baseline withdrawal thresholds to von Frey stimulation and baseline withdrawal latencies to cold
stimulation (4.5 ºC) and heat stimulation (47.5 ºC) in control and neuropathic rats. Data are pre-
sented as mean ± S.E.M. of 13 groups of 10 rats (CCI) or 4 groups of 11 rats each (control).
(* p<0.05)
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Figure 4.
The effect of i.t.
SHU9119 (A), MTII (B)
and D-Tyr-MTII (C) on
withdrawal thresholds
to von Frey stimulation
in neuropathic rats.
Thresholds are trans-
formed to the loga-
rithm of the applied
force. Differences
between post-injection
and pre-injection
(baseline) value are
plotted.
Data are presented as
mean ± S.E.M. of 10
rats each, except 1.5
mg SHU9119 (N=4)
(* p<0.05 vs. vehicle;
ºp< 0.05 vs. highest
dose of MTII, D-Tyr-
MTII or SHU9119).
tile anti-allodynic effect, as shown by a dose-dependent increase in with-
drawal thresholds to von Frey stimulation (fig. 4A), compared to vehicle
treatment. Peak effects were reached 15 min after injection, resulting in a
withdrawal threshold of up to 170.5 ± 7.25 % of baseline value (mean ±
S.E.M.) with 1.5 µg SHU9119 (fig. 5A).
As for the mechanical withdrawal thresholds, withdrawal latencies to cold
Melanocortins in neuropathic pain
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stimulation also increased upon administration of SHU9119 (fig. 6A). The
cold anti-allodynic effect of  the 2 lowest doses of SHU9119 showed a dose-
dependency as observed for the tactile anti-allodynic effect. However, the
highest dose tested (1.5 µg) only produced a small increase in withdrawal
latencies. This group consisted of only 4 animals and baseline withdrawal
latencies of 2 of these 4 animals were already at cut off value, leaving no
room for a further increase in latency. In the remaining 2 animals latencies,
however, did increase to cut off value in one case and to 174% of baseline in
the other case.Treatment with SHU9119 did not cause any changes in with-
drawal latencies at 47.5°C (data not shown).
In control rats, administration of 1.5 µg SHU9119 had no effect on respons-
es to mechanical, cold or heat stimulation (data not shown).
Administration of MTII and D-Tyr-MTII
In CCI rats, administration of the MC receptor agonist MTII (15, 30, 100
and 500 ng) produced a dose-dependent decrease in withdrawal thresholds
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Figure 5.
Dose-response curves of the effect
of i.t. SHU9119 (A), MTII and D-
Tyr-MTII (B) on von Frey with-
drawal thresholds in neuropathic
rats.Values represent threshold at
30 min post-injection as a percen-
tage of baseline threshold.
Data are presented as mean ±
S.E.M. of 10 rats each, except 1.5
mg SHU9119 (N=4).
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to mechanical stimulation (fig. 4B). 30 min after injection withdrawal
thresholds were reduced to 4.64 ± 0.52% of baseline (mean ± S.E.M) with
the highest dose tested (fig. 5B).
Similarly as for tactile thresholds, MTII dose-dependently decreased with-
drawal latencies at 4.5°C (fig. 6B).The most potent effect was observed with
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Figure 6.
The effect of i.t.
SHU9119 (A), MTII (B)
and D-Tyr-MTII (C) on
withdrawal latencies to
cold stimulation (4.5
ºC) in neuropathic
rats. Differences
between post-injection
and pre-injection
(baseline) value are
plotted.
Data are presented as
mean ± S.E.M. of 10
rats each, except 1.5
mg SHU9119 (N=4)
(* p<0.05 vs. vehicle; º
p< 0.05 vs. highest
dose of MTII, D-Tyr-
MTII or SHU9119).
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the highest dose tested, which reduced latencies to 9.68 ± 5.07 % (mean ±
S.E.M.) of baseline value (fig. 7). As for SHU9119, treatment with MTII
caused no significant changes in withdrawal latency to a heat stimulus.
Administration of the more selective MC4 receptor agonist D-Tyr-MTII
produced similar results as those observed with MTII, with approximately 10
times higher doses (0.3, 1 and 3 µg) resulting in a dose-dependent decrease
in withdrawal thresholds to von Frey stimulation (fig. 4C) and in withdraw-
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Figure 7.
Dose-response curves of the
effect of i.t. MTII and D-Tyr-MTII
on withdrawal latencies to cold
stimulation (4.5 ºC) in neuro-
pathic rats.Values represent
threshold at 30 min post-injec-
tion as a percentage of baseline
threshold.
Data are presented as mean ±
S.E.M. of 10 rats each.
Figure 8.
Summary of the effects of i.t. administration of the MC3-R selective ligand Nle-g-MSH (5 µg), the
MC4-R selective ligands MTII (500 ng), D-Tyr-MTII (3 µg) and the MC-R antagonist SHU9119 (1.5
µg) on the responses of CCI and control rats to different stimuli (indicated on X-axis).Values rep-
resent thresholds at 30 min (MTII, D-Tyr-MTII and Nle-g-MSH) or 15 min (SHU9119) post-injection
as a percentage of baseline threshold. Data are presented as mean ± S.E.M. of 11 (control) or 10
(CCI) rats each, except 1.5 mg SHU9119 (N=4 CCI rats).
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al latencies to cold stimulation (fig. 6C).Values were decreased to 14.73 ±
6.04 % and 20.04 ± 5.14 % (mean ± S.E.M.) of baseline values, respectively
(figs. 5B, 7). As for MTII, administration of D-Tyr-MTII had no effect on
withdrawal latencies at 47.5 °C.
In control rats, the highest dose of both ligands (500 ng MTII or 3 µg D-
Tyr-MTII) did not cause any changes in responses to mechanical, cold or
heat stimulation (data not shown).
Co-administration of MTII and SHU9119
Co-administration of 15 ng MTII, a dose which by itself had no effect on
sensory thresholds (figs. 4B, 6B), and 0.5 µg SHU9119 in CCI rats, resulted
in a complete inhibition of the cold and mechanical anti-allodynic effect of
SHU9119 (data not shown).
Administration of Nle-γ-MSH
In CCI rats, a single, high dose (5 µg) of the selective MC3 agonist Nle-γ-
MSH was tested. No decreased or increased response was observed to either
mechanical or thermal stimulation (data not shown).
In figure 8 a summary of the described effects of the different MC receptor
ligands is presented.
Grooming behavior
Total grooming scores after injection of saline or 500 ng MTII into the cis-
terna magna were 50.67 ± 6.39 and 54.5 ± 14.5, respectively (mean ±
S.E.M.).These values were not significantly different (data not shown).
Discussion
In the spinal cord the expression of the MC4 receptor overlaps with that of
the POMC derived peptides α-MSH and ACTH in nociception-associated
areas
19,21
.Therefore we hypothesized that at the spinal level, the MC-system
is involved in the processing of nociceptive information. Here we show for
the first time that changes in the spinal cord MC-system occur following a
Melanocortins in neuropathic pain
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chronic constriction injury (CCI) to the rat sciatic nerve, a lesion that caus-
es neuropathic pain.As shown in fig. 2, in situ binding of the synthetic MC
receptor ligand 
125
I-NDP-MSH is increased in lumbar (L4-L6, correspon-
ding with sciatic nerve input) spinal cord sections of CCI rats as compared
to sham operated animals, suggesting an upregulation of spinal cord MC
receptors. It is not likely that these changes are caused by the profound deaf-
ferentation associated with a CCI lesion per se
29,30
, since van der Kraan et al.
19
have shown that crushing the sciatic nerve, another lesion producing exten-
sive nerve fibre loss, did not lead to significant differences in 
125
I-NDP-MSH
binding levels compared to sham surgery.
Of the anatomic regions we investigated, which were the regions with the
highest intensity of binding, the superficial dorsal horn both ipsi- and con-
tralateral to the lesion showed this increased binding. Bilateral changes asso-
ciated with CCI have been described for other systems as well, including
opioid binding sites
31
, calcitonin-gene related peptide and substance P
immunoreactivity
32
, metabolic and nitric oxide synthase activity
33,34
and
transsynaptic degeneration
35
. The contralateral changes might be explained
by changes in primary afferents that cross the midline, commissural connec-
tions between intrinsic spinal neurons
36
or descending control systems affect-
ing both sides of the spinal cord
37
.
The superficial dorsal horn, the area that displayed an increased 
125
I-NDP-
MSH binding in our experiments, corresponds with the predominant entry
zone of cutaneous fine diameter primary afferents of the sciatic nerve. In
contrast, the gray matter surrounding the central canal, an area that receives
mostly visceral input, showed no differences in binding.These findings sug-
gest that changes in the endogenous MC-system in the spinal cord might be
involved in the increased pain state associated with the CCI lesion, and
prompted us to investigate whether tonic activity of the MC-system con-
tributed to this increased sensitivity.As shown in figs. 4-6, administration of
SHU9119, an antagonist at the MC4-receptor, induced a significant anti-
allodynic effect in both the cold- and mechanical stimulation tests, indicat-
ed by an increased withdrawal latency upon immersion in a 4.5 °C water-
bath and a higher threshold to von Frey stimulation, respectively.The obser-
vation that administration of an MC receptor antagonist produced hypoal-
gesia by itself indeed suggests a tonic influence of the MC-system on noci-
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ceptive transmission.
The increase in MC receptor level in the superficial dorsal horn in CCI rats
suggests an increased sensitivity for MC receptor agonists in neurons in this
area.Treatment with the MC receptor agonist MTII resulted in an opposite
effect compared to SHU9119, producing an increased sensitivity to both
cold and mechanical stimulation. Similar results were obtained with D-Tyr-
MTII, a MC receptor agonist that displays a higher affinity for the MC4
receptor as compared to the MC3 receptor. Co-administration of MTII and
SHU9119 demonstrated the specificity of the anti-allodynic effect of
SHU9119. Injection of 15 ng of MTII, a dose which by itself caused no sig-
nificant changes in nociceptive thresholds, completely blocked the anti-allo-
dynic effect of 0.5 µg of SHU9119, when administered simultaneously,
thereby demonstrating that the effects of these compounds are indeed medi-
ated through the same receptor.Administration of the selective MC3 recep-
tor agonist Nle-γ-MSH had no effect on sensitivity. Since both MTII and
D-Tyr-MTII altered the responses to cold and von Frey stimulation where-
as Nle-γ-MSH had no effect, we suggest that the observed changes in noci-
ception are mediated through the MC4 receptor.
In the present study we administered MC receptor ligands through a can-
nula placed in the cisterna magna , directly into the fluid surrounding the
spinal cord.Adan et al.
38
have demonstrated that a dose of 4.5 pmol MTII is
already sufficient to induce grooming, when administered intracerebroven-
tricularly. In contrast, we demonstrate that a more than 100-fold higher dose
(500 ng, approximately 488 pmol) failed to induce grooming when injected
into the cisterna magna.We cannot exclude the possibility that a small por-
tion of the drugs administered into the cisterna magna will retrogradely
reach the ventricular system and surrounding structures, and that these struc-
tures play a role in the (anti-) nociceptive effects described here. However,
since no grooming was observed after injection of a high dose of agonist, we
suggest that the effects we observed in the present study are predominantly
excerted at the spinal level.
In the dorsal horn, immunoreactivity has been demonstrated for the MC
receptor agonists α-MSH and ACTH as well as for the opioid peptide β-
endorphin
21
, all of which are derived from the POMC peptide. Furthermore,
the µ and δ-opioid receptor subtypes, for which β-endorphin displays a high
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affinity, has also been demonstrated in the same area by immunocytochem-
istry
27,39
.Therefore we hypothesize that the observed anti-allodynic effects of
SHU9119 might be caused by blockade of a tonic influence of endogenous
α-MSH on nociception, through the MC4 receptor in the spinal cord.This
could tip the balance in favor of the anti-nociceptive actions of β-endor-
phin, co-released with α-MSH in the same POMC projection areas, thus
producing analgesia.
The exact source of spinal POMC expression is not known: it might be
intrinsic to the spinal cord
19,20
, but may also originate from a supraspinal
source, namely the nucleus tractus solitarius
21
or the hypothalamus
40,41
. Elias
et al.
40
have demonstrated that hypothalamic POMC expressing neurons
innervate the interomedial lateral cell column (IML) at a thoracic level,
where sympathetic preganglionic cells are located. In this region MC4-R
mRNA is also expressed
42
.
The melanocortin system is suggested to play a role in the regulation of
autonomic function, since centrally administered melanocortins can increase
sympathetic nerve activity
43
, possibly through activation of the MC4 recep-
tor
18,42,44
. Although its exact role is still a matter of debate, there are several
lines of research indicating that the sympathetic nervous system is involved
in neuropathic pain
45-48
. One of the potential mechanisms by which sympa-
thetic activity influences nociception is through an increased norepinephrin
responsiveness in C-fibers, the primary afferents activated by noxious stim-
uli (for review, see Janig et al.
49,50
, Bennett
51
).
In this present study we only demonstrated changes in the MC system in
areas of the spinal cord that correspond to sciatic nerve input.We can how-
ever not exclude the possibility that changes also occur at other spinal lev-
els, or that the ligands we used act through MC receptors located more ros-
trally.Thus, an alternative explanation for the observed effects of MC recep-
tor ligands on neuropathic pain might be a change in sympathetic activity,
mediated at the level of the IML.
As shown in figure 3, baseline values for von Frey and cold stimulation were
significantly lower in CCI rats compared to control rats, confirming the
development of mechanical and cold allodynia associated with the CCI
lesion
22,52
. However, in contrast to other groups
22,52,53
, we observe no differ-
ences in sensitivity to noxious heat between control rats and CCI rats.The
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reason for this discrepancy is not clear  but may result from genetic variabil-
ity between various rat strains.As previously suggested, this may lead to dif-
ferences in predisposition for the development of neuropathic conditions
54
or in sensitivity to noxious stimuli, due to variations in endogenous opiate
systems or adrenergic sensitivity
55,56
.
Interestingly, we only observed effects of the MC receptor ligands in CCI
rats, and only on responses to cold and mechanical stimulation. From a clin-
ical point of view this is promising, since in this study the effects of
melanocortins appear to be specific for the allodynia associated with a neu-
ropathic pain state, without altering normal pain sensation by inducing a
more general analgesia.This specificity for the hyperalgesia underlying neu-
ropathic pain without affecting baseline pain detection has also been report-
ed for the α2-adrenergic agonist tizanidine
57
.
In summary, in this present study we show that intrathecally administered
MC receptor ligands alter the sensitivity to cold and mechanical stimulation
in a rat model for neuropathic pain, the CCI. Our data suggest that these
effects are mediated through the MC4 receptor located in the spinal cord.
SHU9119 produces profound anti-allodynia, whereas MTII and D-Tyr-
MTII increase sensitivity to cold and mechanical sensitivity. We therefore
suggest that selective MC4 receptor antagonists may be of value in the treat-
ment of neuropathic pain, and that further research into the mechanisms
through which the effects of these ligands are excerted is needed.
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Abstract
In the present study we investigated the involvement of the spinal cord melanocortin (MC)
system in neuropathic pain. Since we recently demonstrated that MC receptor ligands
acutely alter nociception in an animal model of neuropathic pain we here tested whether
chronic administration was also efficacious. We hypothesise that chronic blockade of the
spinal MC system might decrease sensory abnormalities associated with this condition.The
effects of the MC receptor antagonist SHU9119 (0.5 µg/day) and agonist MTII (0.1 µg/day)
were evaluated in rats with a chronic constriction injury of the sciatic nerve. Drugs were
continuously infused into the cisterna magna. Antinociceptive effects were measured using
tests involving temperature (10°C or 47.5°C) or mechanical (von Frey) stimulation.
Administration of MTII increased mechanical allodynia whereas SHU9119 produced a pro-
found cold and mechanical anti-allodynia, altering responses to control levels.The anti-allo-
dynic effects of SHU9119 were very similar to those produced by the α2–adrenergic ago-
nist tizanidine (50 µg/day). The effects of SHU9119 and MTII are most likely mediated
through the MC4 receptor, as this is the only MC receptor subtype present in the spinal
cord.We conclude that chronic administration of MC4 receptor antagonists might provide
a promising tool in the treatment of neuropathic pain.
Chapter 5
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Introduction
Neuropathic pain (pain after a lesion to the central or peripheral nervous
system) remains one of the most difficult forms of pain to treat.
Conventional treatment with the two major classes of analgesics, non-
steroidal anti-inflammatory drugs and opioids, is seldom effective. Moreover,
the wide variety of drugs currently used in the treatment of neuropathic
pain, including tricyclic antidepressants, anticonvulsants, systemic administra-
tion of local anesthetics, and NMDA receptor antagonists do not often pro-
vide adequate pain relief
1
.
Extensive research using experimental animal models has led to the discov-
ery of an array of potential new drug targets
2
. A possible target in the con-
trol of neuropathic pain that has received very little attention is the
melanocortin (MC) system. Several lines of research have suggested an
involvement of the MC system in nociception. Previous studies have
demonstrated hyperalgesia in different tests of acute nociception after intrac-
erebroventricular administration of the melanocortins α-MSH (α-
melanocyte stimulating hormone) and ACTH (adrenocorticotropic hor-
mone)
3,4
. In addition, the analgesic effects of morphine and β-endorphin are
antagonized by these peptides
5
.
At the spinal cord level, the presence of a functional MC system is suggest-
ed by the presence of the pro-opio-melanocortin (POMC) derived peptides
ACTH and  α-MSH, and the MC-4 receptor
6,7
. Interestingly, these are all
co-localized in the superficial dorsal horn, an area that is important in noci-
ception.Taken together, these findings suggest an involvement of the spinal
cord MC system in nociceptive transmission.
Recently we investigated the spinal cord MC system as a new drug target
for the control of neuropathic pain.We have shown that a chronic constric-
tion injury (CCI) of the sciatic nerve
8
, a condition that causes a syndrome
similar to human neuropathic pain, induces an increase in 
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I-NDP-MSH
binding to the spinal cord, suggesting an increase in MC receptors.
Furthermore, acute intrathecal administration of the MC receptor antagonist
SHU9119 (directly into the cisterna magna) reduced cold and mechanical
allodynia in CCI rats, whereas MC-4  selective agonists had the opposite
effect
9
.
Chronic blockade of MC-R
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Most drugs used in animal models of neuropathic pain are tested in an acute
administration paradigm. Since it is a chronic form of pain, drugs suitable for
chronic administration, providing long-lasting pain relief, are interesting
from a clinical point of view. In light of the anti-allodynic effect of acutely
administered SHU9119, in the present study we have investigated the effects
of this compound, as well as the MC receptor agonist MTII, upon chronic
administration.
The effects of these MC receptor ligands were compared with those of the
α2-adrenergic agonist tizanidine, of which the anti-nociceptive and anti-
allodynic actions in experimental animals have been well documented
10,11
.
Materials and Methods
All procedures in this study were performed according to the Ethical
Guidelines of the International Association for the Study of Pain
12
and
approved of by the Ethics Committee on Animal Experiments of the
Utrecht University.
Animals and drugs
Forty-eight male Wistar rats weighing 350-400 g at the start of the study
were used. They were socially housed in groups of 2-3 on a sawdust bed-
ding. The animals were kept at a 12/12h light/dark cycle, with food and
water available ad libitum.
Animals were randomly assigned to different treatment groups. CCI rats
were treated with either vehicle (N=10), SHU9119, 0.5 µg/day (N=11),
tizanidine hydrochloride, 50 µg/day (N=7) or MTII, 0.1 µg/day (N=10).
Sham rats (N=10) were treated with vehicle.
SHU9119 (cyclo-[Nle4, Asp5, D-Nal(2)7, Lys10]α-MSH-(4-10)) was syn-
thesized using 9-fluorenyl-methoxycarbonyl (fmoc)-based solid phase syn-
thesis as reported elsewhere
13
and purified using reversed phase preparative
high-pressure liquid chromatography (HPLC) to a purity of ± 90%, estimat-
ed after analysis by analytical HPLC at 215 nm. Molecular weight was con-
firmed by mass spectrometry performed on a Micromass Quattro sq.
Chapter 5
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Tizanidine hydrochloride was purchased from Novartis Pharma AG (Basel,
Switzerland). MTII (Melanotan-II or cyclo-[Nle4, Asp5, D-Phe7, Lys10]α-
MSH-(4-10)) was purchased from Bachem Feinchemicalien (Bubendorf,
Switzerland).
Drugs were dissolved in saline and continuously administered into the cis-
terna magna via an Alzet osmotic minipump (Charles River, Someren, the
Netherlands, type 2002, pump speed 0.5 µl/hr for 14 days).
Surgery
Prior to surgery, all animals were anesthetized with a single subcutaneous
injection of Hypnorm (Janssen Pharmaceutical LTD., Grove, Oxford) con-
taining 0.315 mg/mL fentanyl citrate and 10 mg/mL fluanisone (a buty-
rophenone), at a dose of 0.3 mL/kg bodyweight.
Chronic constriction injury: a chronic constriction injury was produced by
placing four loose ligatures of 4-0 chromic catgut (Ethicon INC.,
Norderstedt) around the nerve as previously described by Bennet and Xie
8
.
Subsequently the incision was closed with silk sutures and the animals were
allowed a 2-3 day recovery period. For the sham condition the same proce-
dure was performed except placement of the ligatures.
Cisterna Magna cannulation: two weeks after the initial surgery a steel cister-
na magna cannula (20 * 0.4 mm) was placed as described by Lankhorst et
al
14
. An Alzet osmotic minipump (type 2002, pumping rate 0.5 µL/h, dura-
tion 14 days), filled with the appropriate solution, was implanted in the right
flank and connected to the cannula by subcutaneously tunnelled polyethyl-
ene tubing (PP 25).The incision in the flank was closed with silk sutures.
Since the tube connecting the minipump to the cannula was filled with
saline and as a consequence of the length of the tube and pump speed, the
drugs were delivered into the cerebrospinal fluid (CSF) starting three days
after implantation of the pumps.This allowed the animals a three day recov-
ery period before testing was initiated.
The day on which the drugs were delivered into the CSF is referred to as
‘treatment day 1’.
Chronic blockade of MC-R
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Sensory testing
1 Temperature stimulation test
Withdrawal latency to a temperature stimulus was measured by immersing
the hind paws on each side into a 10°C or 47.5°C water bath. Upon immer-
sion of the paw an electronical circuit including a timer was closed.
Withdrawal of the paw resulted in a discontinuation of the circuit which
stopped the timer, thus allowing a precise registration of the withdrawal
latency time. Cut-off time was set at 10 s to avoid skin damage. Interval time
between consecutive tests was at least 10 min to allow restoration of origi-
nal foot temperature.
2 Mechanical stimulation test
Prior to testing, each rat was placed in a plastic testing box with a metal mesh
floor, and allowed to acclimatize to this environment. Mechanical allodynia
was determined by measuring the paw withdrawal threshold following prob-
ing of the foot plantar surface with a series of calibrated von Frey filaments
(Stoelting,Wood Dale, IL), ranging from 1.08 to 21.09 g. Probing was only
performed if the hind paw was in contact with the mesh floor, to correct for
paw lifting in response to spontaneous pain. Filaments were applied to the
mid-plantar surface of both feet through the mesh floor until the filament
bent, and kept in this position for 6-8 s15.The smallest force that elicited a
foot withdrawal response was considered the threshold stimulus.
Temperature and mechanical stimulation tests were performed the day
before the beginning of pharmacological treatment (‘baseline value’) and at
2-3 day intervals thereafter (‘treatment days 1-10’).Throughout the experi-
ment bodyweight was monitored at regular intervals.
Statistical analysis
Data are plotted starting from the day before the onset of treatment (‘base-
line’) through treatment day 10.Withdrawal latencies are expressed as mean
± standard error of the mean (SEM). Withdrawal thresholds to von Frey
stimulation are expressed as median and 25th to 75th percentile range, with
values plotted on a logarithmic scale.
Differences in bodyweight between treatment groups were compared using
Chapter 5
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a repeated measures analysis of variance (ANOVA). All other data were ana-
lyzed using non-parametric tests.To obtain a linear scale of perceived force
in the mechanical stimulation test, withdrawal thresholds were converted to
the log of the actual bending force of the filament. Statistical analysis was
performed on the transformed data. Differences in baseline values were ana-
lyzed using a Mann-Whitney U test. Overall group differences in mechani-
cal and temperature stimulation tests were analyzed by a Kruskall-Wallis test.
The effects of the different drugs were compared to the vehicle-treated
CCI-group and, in case of a significant difference, to the sham group using
a Mann-Whitney U test with Bonferroni-correction. In the mechanical
stimulation test, for the CCI group treated with MTII, thresholds on treat-
ment days 1 and 3 were compared to baseline values using a paired T-test.
Results were considered significant when p<0.05. For the cold and mechan-
ical stimulation tests, the effect of SHU9119 or tizanidine was quantified as
the percentage of maximum possible effect (%MPE), using the following
formula:
% MPE = 100 x (postdrug value – baseline value) / (cutoff value – baseline
value)
Results
At the end of the experiments, proper placement of cannulas and connec-
tion to the minipumps was checked. Pump reservoirs were checked to con-
trol accurate drug delivery. All reservoirs were empty. One animal was
excluded because of improper connection of the pump and one animal died
during anesthesia. Both were CCI animals.There were no significant differ-
ences in bodyweight between treatment groups at any time point (data not
shown).
All CCI groups developed a cold allodynia of the ligated hindpaw as indi-
cated by a significant reduction in withdrawal latency upon immersion in a
10°C waterbath (mean pre-drug value ± SEM for all CCI groups: 5.5 ± 0.7
sec.). In the sham group none of the animals showed signs of cold allodynia
(mean withdrawal latency ± SEM: 9.5 ± 0.3 sec).The cut-off latency for the
test was 10 s. No signs of cold allodynia developed in the contralateral hind-
Chronic blockade of MC-R
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paw of either sham or CCI animals.
There were no significant differences in baseline responses to heat (47.5 °C)
stimulation between sham and CCI animals on either side.
CCI animals displayed a tactile allodynia on the ligated side as shown by a sig-
nificant decrease in withdrawal threshold to von Frey stimulation (pre-drug
value ± SEM for all groups of  8.5 [6.2-8.5] g) (median and [25th – 75th per-
centile]) . Sham animals failed to respond to any filament up to the maximum
of 21.09 g, as was the case for the contralateral hindpaw of CCI animals.
These data are summarized in figure 1.
Drug effects
1 Temperature stimulation test
As shown in fig. 2A, treatment with SHU9119 (500 ng/day) significantly
prolonged withdrawal latency of the ligated hindpaw to a cold stimulus as
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Figure 1.
Baseline withdrawal
latencies to cold (10
ºC) and heat (47.5 ºC)
stimulation and base-
line withdrawal thresh-
olds to von Frey stimu-
lation in sham (black
bars) and CCI (open
bars) rats.
Measurements were
taken on the unoper-
ated (A) and experi-
mental  (B) hind paw.
Withdrawal latencies
are presented as mean
± SEM and withdrawal
thresholds as median
and 25th-75th per-
centile range (logarith-
mic scale) of 10
(sham) or 36 rats
(CCI). (* p<0.05 vs.
sham)
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compared to the vehicle CCI-group (p<0.05 on treatment days 1 and 3),
restoring latencies to near cut-off values (non-significant vs. sham). %MPE
was 86.9 ± 8.1 and 90.7 ± 9.3 respectively.
This effect of SHU9119 was similar to that of 50 µg tizanidine/day (p<0.05
vs. vehicle CCI-group on treatment days 1 and 3) (fig. 2A); %MPE was 97.3
± 2.7 and 100 ± 0%, respectively. On treatment day 5 withdrawal latencies
decreased again in both SHU9119 and tizanidine treated groups and did not
significantly differ from vehicle CCI-group throughout the rest of the test-
ing period.
Treatment with MTII (100 ng/day) resulted in a transient, non-significant
decrease in withdrawal latencies of the ligated hindpaw (fig. 2A).
All treatments were ineffective in causing any significant changes in with-
drawal latencies to the cold stimulus on the contralateral  side. Also, there
were no significant differences in withdrawal latency to a heat stimulus
between the vehicle treated CCI group and any of the other treatment
groups on eihter side (data not shown).
Chronic blockade of MC-R
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Figure 2.
The effect of  SHU9119 (500 ng/day), MTII (100 ng/day) and tizanidine (50 µg/day) on withdrawal
latencies to cold (10 ºC) stimulation (A) and withdrawal thresholds to mechanical stimulation (B) in
rats with a chronic constriction injury. Drugs were continuously administered in the cisterna magna
by an osmotic minipump. Data are plotted from the day before beginning of treatment (‘baseline’)
to treatment day 10.
Withdrawal latencies are presented as mean ± SEM and withdrawal thresholds as median and 25th-
75th percentile range (logarithmic scale) of 10 (sham, CCI+vehicle and SHU9119), 9 (MTII) or 7
(tizanidine) rats each. (* p<0.05, SHU9119 vs. vehicle; º p< 0.05, tizanidine vs. vehicle; # p<0.05 vs.
baseline)
A B
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2 Mechanical stimulation test 
As shown in fig. 2B, treatment with SHU9119 (500 ng/day) increased the
withdrawal threshold on the ligated side up to 17.0 [13.2-20.9] and 20.9
[13.2-20.9] g (median and [25th – 75th percentile]) on treatment days 1 and
3; % MPE was 73.0 [26.4-100] and 100 [46.6-100] respectively. These
thresholds were significantly higher than those in the vehicle CCI group
(p<0.05) and did not significantly differ from the maximum threshold as
observed in the sham operated group.
Administration of 50 µg tizanidine/day resulted in a similar increase in
threshold. On treatment days 1 and 3, thresholds were 13.2 [13.2-13.2] and
13.2 [13.2-20.9] respectively (p<0.05 vs vehicle CCI group), with corre-
sponding  % MPE of 46.6 [24.3-52.2] and 46.6 [37.7-100] (median and
[25th – 75th percentile]) Only on treatment day 3 this threshold did not sig-
nificantly differ from the threshold of the sham-operated group.
On treatment day 5 thresholds in both the SHU9119 and tizanidine treated
groups decreased again and were not significantly different from the vehicle
CCI group for the remainder of the testing period.
Treatment with 100 ng MTII/day produced a decrease in withdrawal
thresholds on treatment days 1 and 3 (median and [25th – 75th percentile]
of 4.7 [4.1-5.4] and 5.4 [5.0-5.4]) (fig. 2B).When compared to the vehicle
CCI group, this decrease was not significant, due to a slightly higher base-
line value in the MTII treated group. However, within the MTII treated
group, withdrawal thresholds on treatment days 1 and 3 were significantly
lower than baseline value.
None of the treatments caused any significant changes in withdrawal thresh-
old on the contralateral side (data not shown).
Discussion
Here we demonstrate that the MC receptor antagonist SHU9119, when
infused chronically into the cisterna magna, reduces cold and mechanical
allodynia in CCI rats. Infusion of MTII, a MC receptor agonist, into the cis-
terna magna induces an increased sensitivity to mechanical stimulation. Since
the MC4 receptor is the only  MC receptor subtype known to be present in
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the spinal cord
16
, it is most likely that the observed effects of MTII and
SHU9119 are mediated through this receptor, as we have previously sug-
gested
9
.
The mechanism through which SHU9119 alleviates allodynia remains to be
elucidated. Possibly the endogenous MC receptor agonist αMSH, released in
the dorsal horn
6
exerts a tonic influence on nociception. Consistent with this
view is the induction of hyperalgesia upon intracerebroventricular adminis-
tration of MC receptor agonists
3,4
and the observed upregulation of spinal
cord MC receptors in CCI rats
9
, which could contribute to the increased
sensitivity associated with the lesion.We hypothesize that the anti-allodynic
effects of SHU9119 are caused by a blockade of  the endogenous αMSH
tonus.
Melanocortins modulate a variety of body functions, including fever, immu-
nity and body weight homeostasis
17
.The latter has received much attention,
since the MC4 receptor has been shown to play a role in disorders of ener-
gy balance, such as obesity
18
. In rats, MTII and SHU9119 respectively inhib-
it and stimulate food intake, when administered intracerebroventricularly
19
.
With the use of melanocortins as possible analgesic drugs, changes in body-
weight are unwanted side effects.Therefore, in the present study, drugs were
continuously infused into the cisterna magna, downstream of the cere-
broventricular system. The osmotic minipumps we used have a very low
infusion speed (0.5 µL/h), thus allowing a very gradual release of drugs
without creating pressure in the direction of the ventricular system. The
continuity and speed of drug delivery by the minipums have been verified
earlier in our laboratory (unpublished results). Since at the end of the study
pump reservoirs were empty, it is very unlikely that there was backflow from
CSF into the pumps. Thus in this way drugs were delivered directly in the
CSF surrounding the spinal cord, where their proposed site of action, the
spinal MC4 receptor, is located.The doses of SHU9119 and MTII we used
here (0.5 and 0.1 µg/day, respectively) have been shown in rats to readily
affect bodyweight when administered intracerebroventricularly
19
. Here we
show that the anti-allodynia induced by chronic administration of the MC
receptor antagonist SHU9119 into the cisterna magna is not accompagnied
by any changes in bodyweight, further confirming a spinal site of action.
The magnitude of the anti-allodynic effects we find with SHU9119 are
Chronic blockade of MC-R
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comparable to those of tizanidine, and were so large that responses were nor-
malized to control (sham) levels. Moreover, the cold anti-allodynia corre-
sponds well with that described by Leiphart et al.
10
(over 80% decrease in
paw withdrawal after 50 µg tizanidine intrathecally). In contrast, they
describe an MPE of only 19% in the paw pinch test whereas we observed a
MPE of up to 46% in the von Frey test with 50 µg tizanidine/day. This
might be explained by the fact that the paw pinch test measures pressure
hyperalgesia, whereas the von Frey stimulation we used measures mechani-
cal allodynia. It is however difficult to make full comparisons between tizani-
dine and SHU9119, since here only single doses are tested and the mecha-
nisms of action (involving the α-adrenoreceptors for tizanidine and the
melanocortin receptors for SHU9119) are clearly distinct.
In contrast to other groups
8,20
we found no differences in heat sensitivity
between CCI and control rats. This discrepancy might result from genetic
differences between various rat strains, leading to variations in the predis-
postion for the development of neuropathic conditions
21
or in sensitivity to
noxious stimuli
22
. In the present study, none of the drugs tested induced
changes in the CCI animals’ responses to heat. Also we have previously
demonstrated that injecting  a high dose of MTII (500 ng) or SHU9119 (1.5
µg) into the cisterna magna does not affect pain perception in control rats9.
Taken together, these data suggest that both tizanidine and the
melanocortins specifically affect the sensory abnormalities associated with
the neuropathic pain state, without affecting normal pain perception. Our
data confirm previous reports of this selectivity of tizanidine effects in neu-
ropathic pain
10,11
.
In spite of its potent antinociceptive actions in experimental animals, clini-
cal trials performed with tizanidine had less promising results. In patients
with trigeminal neuralgia, the efficacy of tizanidine was inferior to that of
carbamazepine
23
, and there was a rapid recurrence of painful attacks during
tizanidine treatment
24
.
Levy et al.
11
have reported that upon chronic intrathecal infusion of tizani-
dine, after several days rats became tolerant to its analgesic effects. In the
present study, we observed a similar time-course of the effects of tizanidine.
Surprisingly, we found that also MTII and SHU9119 had only temporarily
effects. Possibly the organism quickly adapts to both a lack of tonic α-MSH
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as well as a continous (over-)stimulation of MC receptors, as occur with
chronic infusion of SHU9119 and MTII, respectively.These adaptations or
development of tolerance might be suppressed by using other dosages of
drugs or different drug administration regimens such as repeated injections
at various intervals. Future experiments, employing these strategies, will be
helpful in further addressing this question.
However, this rapid decline of effects of the melanocortins should not
exclude melanocortin antagonists from further consideration in the treat-
ment of neuropathic pain in humans, since differences in the speed of the
development of tolerance between rats and humans do occur. For instance,
tolerance to intrathecal morphine develops quickly in rats in several tests of
acute nociception
25
, whereas in humans morphine tolerance can take sever-
al months to develop and can provide long-lasting adequate pain relief in
cancer pain
26
and non-malignant pain
27
.
In summary, we demonstrate that chronic intrathecal infusion of the MC
receptor antagonist SHU9119 has profound anti-allodynic effects in rats
with a chronic constriction injury of the sciatic nerve.We suggest that these
effects are mediated through the spinal cord MC4 receptor. SHU9119
appears to be specifically effective in altering the sensory abnormalities asso-
ciated with the neuropathic pain state, without affecting normal pain per-
ception. Therefore we suggest that selective MC4 antagonists might be of
value in the treatment of neuropathic pain.
Acknowledgements
The authors would like to thank Simone Duis and Jan Brakkee for their
technical assistance on the experiments.
proefschrift dorien  30-01-2003  17:42  Pagina 111
Chapter 5
112
References
1. Fields HL, Baron R, Rowbotham MC:
Peripheral neuropathic pain: an approach to
management, Textbook of pain, 4 Edition.
Edited by Melzack R, Wall PD. London,
Harcourt Publishers Ltd, 1999, pp 1523-33
2. Chizh BA, Dickenson AH, Wnendt S: The
race to control pain: more participants,
more targets.Trends Pharmacol Sci 1999; 20:
354-7
3. Sandman CA, Kastin AJ: Intraventricular
administration of MSH induces hyperalgesia
in rats. Peptides 1981; 2: 231-3
4. Williams DWJ, Lipton JM, Giesecke AHJ:
Influence of centrally administered peptides
on ear withdrawal from heat in the rabbit.
Peptides 1986; 7: 1095-100
5. Wiegant VM, Gispen WH, Terenius L, De
Wied D:ACTH-like peptides and morphine:
interaction at the level of the CNS.
Psychoneuroendocrinology 1977; 2: 63-70
6. Tsou K, Khachaturian H, Akil H, Watson SJ:
Immunocytochemical localization of pro-
opiomelanocortin-derived peptides in the
adult rat spinal cord. Brain Res 1986; 378:
28-35
7. van der Kraan M, Tatro JB, Entwistle ML,
Brakkee JH, Burbach JP, Adan RA, Gispen
WH: Expression of melanocortin receptors
and pro-opiomelanocortin in the rat spinal
cord in relation to neurotrophic effects of
melanocortins. Mol.Brain Res 1999; 63: 276-
86
8. Bennett GJ, Xie YK: A peripheral mononeu-
ropathy in rat that produces disorders of
pain sensation like those seen in man. Pain
1988; 33: 87-107
9. Vrinten DH, Gispen WH, Groen GJ, Adan
RA:Antagonism of the melanocortin system
reduces cold and mechanical allodynia in
mononeuropathic rats. J Neurosci 2000; 20:
8131-7
10. Leiphart JW, Dills CV, Zikel OM, Kim DL,
Levy RM: A comparison of intrathecally
administered narcotic and nonnarcotic anal-
gesics for experimental chronic neuropathic
pain. J Neurosurg 1995; 82: 595-9
11. Levy R, Leiphart J, Dills C:Analgesic action of
acute and chronic intraspinally administered
opiate and alpha 2-adrenergic agonists in
chronic neuropathic pain. Stereotact Funct
Neurosurg 1994; 62: 279-89
12. Zimmermann M: Ethical guidelines for inves-
tigations of experimental pain in conscious
animals. Pain 1983; 16: 109-10
13. Schaaper WM, Adan RA, Posthuma TA,
Oosterom J, Gispen WH, Meloen RH:
Synthesis of cyclic alpha-MSH peptides.
Letters in Peptide Science 1998; 5: 205-8
14. Lankhorst AJ, Duis SE, ter Laak MP, Joosten
EA, Hamers FP, Gispen WH: Functional
recovery after central infusion of alpha-
melanocyte-stimulating hormone in rats
with spinal cord contusion injury. J
Neurotrauma 1999; 16: 323-31
15. Chaplan SR, Bach FW, Pogrel JW, Chung JM,
Yaksh TL: Quantitative assessment of tactile
allodynia in the rat paw. J Neurosci Methods
1994; 53: 55-63
16. Mountjoy KG, Mortrud MT, Low MJ, Simerly
RB, Cone RD: Localization of the
melanocortin-4 receptor (MC4-R) in neu-
roendocrine and autonomic control circuits
in the brain. Mol Endocrinol 1994; 8: 1298-
308
proefschrift dorien  30-01-2003  17:42  Pagina 112
Chronic blockade of MC-R
113
17. Tatro JB: Receptor biology of the
melanocortins, a family of neuroim-
munomodulatory peptides.
Neuroimmunomodulation 1996; 3: 259-84
18. Mountjoy KG,Wong J: Obesity, diabetes and
functions for proopiomelanocortin-derived
peptides. Mol Cell Endocrinol 1997; 128:
171-7
19. Grill HJ, Ginsberg AB, Seeley RJ, Kaplan JM:
Brainstem application of melanocortin
receptor ligands produces long-lasting
effects on feeding and body weight. J
Neurosci 1998; 18: 10128-35
20. Kupers RC, Nuytten D, De-Castro-Costa M,
Gybels JM: A time course analysis of the
changes in spontaneous and evoked behav-
iour in a rat model of neuropathic pain. Pain
1992; 50: 101-11
21. Wiesenfeld-Hallin Z, Hao JX, Xu XJ,
Aldskogius H, Seiger A: Genetic factors influ-
ence the development of mechanical hyper-
sensitivity, motor deficits and morphological
damage after transient spinal cord ischemia
in the rat. Pain 1993; 55: 235-41
22. Lee DH, Chung K, Chung JM: Strain differ-
ences in adrenergic sensitivity of neuropath-
ic pain behaviors in an experimental rat
model. Neuroreport 1997; 8: 3453-6
23. Vilming ST, Lyberg T, Lataste X:Tizanidine in
the management of trigeminal neuralgia.
Cephalalgia 1986; 6: 181-2
24. Fromm GH, Aumentado D, Terrence CF: A
clinical and experimental investigation of the
effects of tizanidine in trigeminal neuralgia.
Pain 1993; 53: 265-71
25. Nabeshima T,Yamada S, Sugimoto A, Matsuno
K, Kameyama T: Comparison of tizanidine
and morphine with regard to tolerance-
developing ability to antinociceptive action.
Pharmacol Biochem Behav 1986; 25: 835-41
26. Penn RD, Paice JA, Gottschalk W, Ivankovich
AD: Cancer pain relief using chronic mor-
phine infusion. Early experience with a pro-
grammable implanted drug pump. J
Neurosurg 1984; 61: 302-6
27. Angel IF, Gould HJJ, Carey ME: Intrathecal
morphine pump as a treatment option in
chronic pain of nonmalignant origin. Surg
Neurol 1998; 49: 92-8
proefschrift dorien  30-01-2003  17:42  Pagina 113
114
Dorien BW 06-02  06-02-2003  16:30  Pagina 114
115
6Interaction betweenthe spinalmelanocortin andopioid systems in arat model of neuropathic pain
Dorien H.Vrinten
Willem Hendrik Gispen
Cor J. Kalkman
Roger A.H.Adan Anesthesiology, accepted
proefschrift dorien  30-01-2003  17:42  Pagina 115
Abstract 
We recently demonstrated that administration of the melanocortin-4-receptor (MC4R)
antagonist SHU9119 decreased neuropathic pain symptoms in rats with a sciatic chronic
constriction injury (CCI).We hypothesised that there is a balance between tonic pro-noci-
ceptive effects of the spinal MC system and tonic anti-nociceptive effects of the spinal opi-
oid system. We therefore investigated a possible interaction between these two systems,
and tested whether opioid effectiveness could be increased through modulation of the
spinal MC system activity.
In CCI rats, MC and opioid receptor ligands were administrered through a lumbar spinal
catheter and their effect on mechanical allodynia was assessed by von Frey probing.
Naloxone (10-100 µg) dose-dependently increased allodynia (% of maximum possible
effect (%MPE) of 67 ± 9%), which is in agreement with a tonic anti-nociceptive effect of
the opioid system. SHU9119 decreased allodynia (%MPE of 60 ± 13%) and this effect
could be blocked by a low dose of naloxone (0.1 µg), which by itself had no effect on with-
drawal thresholds. Morphine (1–10 µg) dose-dependently decreased allodynia ( %MPE of
73 ± 14% with the highest dose tested).When 0.5 µg of SHU9119 (%MPE of 47 ± 14%)
was given 15 minutes prior to morphine there was an additive anti-allodynic effect of both
compounds. Together, these data confirm that there is an interaction between the spinal
MC and opioid systems and that combined treatment with MC4-R antagonists and opi-
oids might possibly contribute to the treatment of neuropathic pain.
Chapter 6
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Introduction
Neuropathic pain is characterised by allodynia (pain due to a normally non-
painful stimulus) and hyperalgesia (increased pain in response to a normally
painful stimulus). It has become clear that numerous pathophysiological
changes in response to neuronal or axonal damage contribute to neuropath-
ic pain
1,2
. Not only neuroatomical changes occur, such as loss of axotomised
primary afferent fibers
3
, apoptotic cell loss
4
and reorganization of dorsal horn
circuitry
5
, but also the expression of different neurotransmitters and their
receptors in sensory neurons is altered. Such plasticity has been described in
a number of messenger systems, including substance P, calcitonin-gene relat-
ed peptide, cholecystokinin and neuropeptide Y
6,7
.We recently demonstrat-
ed that such plasticity also occurs in the spinal melanocortin (MC) system,
as demonstrated by an upregulation of MC4-receptors (MC4-R) in the
spinal cord dorsal horn in a rat model for neuropathic pain, the chronic con-
striction injury (CCI)
8,9
. Since MCs have been shown to induce hyperalge-
sia
10,11
, this increase in spinal MC4-R might contribute to the increased sen-
sitivity in neuropathic pain, through activation by the endogenous MC-R
agonist α-MSH, which is also known to be present in the dorsal horn
12
.
An interaction between the central MC and opioid system has been
described previously. MCs can reduce morphine induced analgesia
13,14
inhib-
it the development of opioid tolerance
13,15
, counteract opioid addiction
16
and
induce morphine withdrawal-like symptoms
17
. However, it is not known if
such a functional antagonism between the MC and opioid system also exists
at the spinal level.
It is generally accepted that in neuropathic pain, opioids are less effective.To
obtain adequate pain relief high doses of opioids are needed
18
, thus their use
is often limited by unwanted side effects. Possible explanations for this right-
shift in the dose response curve of opioids include a loss of opioid receptors
on primary afferent terminals after axotomy
19,20
and an increased activity of
endogenous anti-opioids such as dynorphin
21
or cholecystokinin
22,23
in the
spinal cord. Considering the functional antagonism between the MC and
opioid system it is possible that the aforementioned changes in the spinal
MC system in neuropathic pain
9
might also contribute to the reduced anal-
gesic effect of morphine in this condition.
MC and opioid interaction
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We therefore investigated a possible interaction between MC and opioid sys-
tems at the spinal level, by administering different combinations of the opi-
oid receptor antagonist naloxone and agonist morphine, and the MC4
receptor antagonist SHU9119 and agonist MTII. We hypothesized that
through modulation of the activity of the spinal MC system it is possible to
increase the effectiveness of opioids in neuropathic pain.
Materials and methods
Animals
30 Male Wistar rats weighing 250-300 g at the start of the study were used.
Animals were housed in groups of 2-3 in plastic cages on sawdust bedding.
They were kept at a 12/12hr light/dark cycle, with food and water available
ad libitum. All testing procedures in this study were performed according to
the Ethical Guidelines of the International Association for the Study of
Pain
24
and approved of by the Ethics Committee on Animal Experiments of
Utrecht University.
Surgery
Animals were anesthetized with a single intramuscular injection of
Hypnorm (Janssen Pharmaceutical LTD., Grove, Oxford) containing 0.315
mg/ml fentanyl citrate and 10 mg/ml fluanisone, at a dose of 1 ml/kg body-
weight.
4 Ligatures were placed around the right sciatic nerve, as previously
described by Bennett and Xie
8
, and the incision was closed with silk sutures.
Two weeks after the CCI lesion rats were anesthetized with a mixture of
O2/N2O (1:2) and 2.5% halothane. A lumbar spinal catheter was placed, as
described by Storkson et al.
25
, and subcutaneously tunneled to the neck
region.After recovery from anesthesia, and also at the end of all experiments,
proper placement of the catheters was checked by injecting 15 µl of 2%
lidocaine, which gives an immediate and short-lasting motor paralysis of the
hindlimbs upon intraspinal injection. Due to incorrect placement of the
spinal catheter 3 rats were excluded from this study, thus leaving a total of 27
animals.They were allowed to recover before testing was initiated.
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Drugs
For in vivo administration MTII (Melanotan-II or cyclo-[Nle4, Asp5, D-
Phe7, Lys10]α-MSH-(4-10)), SHU9119 (cyclo-[Nle4, Asp5, D-Nal(2)7,
Lys10]α-MSH-(4-10)), naloxone (naloxone-hydrochloride) and morphine
(morphine-hydrochloride) were used. MTII was purchased from Bachem
Feinchemicalien (Buberdorf, Switzerland); SHU9119 was synthesized using
Fmoc solid phase synthesis as reported elsewhere
26
. Naloxone and morphine
were obtained from the Utrecht University Medical Center Pharmacy.
Drugs were dissolved in 5 µl of saline and injected through the spinal catheter
by means of a 25 µl Hamilton syringe, followed by a saline flush (12 µl).
Treatment paradigms
The following 17 different treatments were given: saline, naloxone (0.1, 10,
30 and 100 µg), SHU9119 (0.5 and 1.5 µg), morphine (1, 3 , 10 and 30 µg),
MTII (0.5 µg), or the following combinations: SHU9119 (1.5 µg) with
naloxone (0.1 µg) pretreatment, morphine (1, 3 or 10 µg) with SHU9119
(0.5 µg) pretreatment, or MTII (1.5 µg) and morphine (100 µg) simultane-
ously. In experiments where a “pre-treatment” was given, the first drug was
given 15 min prior to the second drug.
On a typical testing day all 27 animals were randomly divided into 3 groups
(n= 8-9 each, except for simultaneous administration of MTII and mor-
phine, where n=4). Each group randomly received one treatment, with the
experimenter blinded to the allocation. Hereafter animals were given at least
two days rest, to mimimize any possibility of drug interactions or develop-
ment of tolerance. On the next testing day all animals were again randomly
divided into 3 groups, and 3 other treatments were given.This design was
continued until all treatments had been given to one group of animals.Thus
in total 17 groups were tested, and therefore each animal was used multiple
times on consecutive testing days.
Mechanical stimulation test
Foot withdrawal threshold in response to a mechanical stimulus was deter-
mined using a series of von Frey filaments (Stoelting,Wood Dale, IL), rang-
ing from 1.08 to 21.09 g.Animals were placed in a plastic cage with a metal
mesh floor, allowing them to move freely.They were allowed to acclimatize
MC and opioid interaction
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to this environment prior to the experiment.The filaments were presented
to the midplantar surface as described by Chaplan et al
27
, and the smallest fil-
ament eliciting a foot withdrawal response was considered the threshold
stimulus.
Baseline values were determined and measurements were repeated 60 min
after drug or vehicle administration (in case of a pre-treatment, measure-
ments were taken 60 min after injection of the second drug).
Data analysis and statistics
All data are expressed as mean ± standard error of the mean (S.E.M) for visu-
alization purposes only. Effects of treatments resulting in an increase or
decrease in mechanical allodynia are plotted on a negative or positive axis,
respectively. For the mechanical stimulation test the effect of different drug
treatments was quantified as the percentage of maximum possible effect
(%MPE), using the following formula:
% MPE = 100 x (postdrug value – baseline value) / (cutoff value – baseline
value).
Non-parametric tests were performed to analyze the data: overall group dif-
ferences were analyzed by a Kruskal-Wallis test followed by a 2-tailed
MannWhitney U test to analyze differences between groups. A probability
level of <5% was considered significant.
Results
Baseline mechanical withdrawal thresholds
Two weeks after the CCI lesion, mean baseline withdrawal threshold to von
Frey stimulation was reduced from 20.3 ± 0.4 g to 5.3 ± 0.6 g, confirming
the presence of mechanical allodynia. Baseline withdrawal thresholds were
not altered by placement of the spinal catheters, and remained stable
throughout the testing period.
Administration of naloxone, and SHU9119 with low-dose nalo-
xone pre-treatment.
With increasing doses of naloxone (10, 30 and 100 µg), a significant decrease
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in withdrawal thresholds was observed, with a %MPE of -67.2 ± 9.3 at the
highest dose tested (fig. 1).
1.5 µg SHU9119 increased withdrawal thresholds, with an %MPE of 60.0 ±
13.3. When 0.1 µg naloxone, a dose which by itself had no effect on
mechanical withdrawal thresholds, was administered 15 min prior to
SHU9119 (1.5 µg), this anti-allodynic effect of SHU9119 was largely
decreased (%MPE was reduced to 14.8 ± 10.9, which was not significantly
different from saline, fig. 2).
Co-administration of high dose morphine and high dose MTII
Administration of 0.5 µg MTII significantly decreased withdrawal thres-
holds, with a %MPE of -93.8 ± 6.2, whereas 30 µg of morphine increased
thresholds, with a %MPE of 89.6 ± 10.4.A combination of approximately 3
MC and opioid interaction
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Figure 1. Effects of naloxone
on mechanical allodynia
Effects of spinal administration of
naloxone on mechanical allodynia,
as measured by withdrawal thresh-
olds to von Frey stimulation. Doses
ranged from 0 (saline) to 100 µg
naloxone. Data are presented as %
MPE  (mean ± S.E.M) of 8-9 rats
each, 60 min after injection of
naloxone. (* p<0.01 vs. saline)
Figure 2. Modification of the anti-allo-
dynic effect of SHU9119 by naloxone
Effect of spinal administration of 1.5 µg of
SHU9119 (SHU 1.5), 1 µg of naloxone alone
(Nal 1) or 1 µg naloxone 15 min prior to
SHU9119 (Nal 1, SHU 1.5), on mechanical
allodynia. Mechanical withdrawal thresholds
were assessed by von Frey probing. Data are
presented as % MPE  (mean ± S.E.M) of 8-9
rats each, 60 min after the last injection.
(* p<0.01 vs. saline; o p<0.01 vs. SHU9119
alone)
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times higher doses of both drugs (1.5 µg MTII and 100 µg morphine)
resulted in an intermediate %MPE of 12.2 ± 9.8, which was not significant-
ly different from saline (fig. 3).
Administration of morphine with SHU9119 pre-treatment
Spinal administration of morphine (1, 3 and 10 µg) produced a significant
anti-allodynic effect, as shown by a dose-dependent increase in withdrawal
thresholds to von Frey stimulation (fig. 4), compared to saline treatment. A
single dose of SHU9119 (0.5 µg) also increased withdrawal thresholds, with
an %MPE of 47.3 ± 13.9.When given 15 min prior to morphine, 0.5 µg of
SHU9119 resulted in an additive and significant increase in withdrawal
thresholds, with a maximum %MPE of 86.2 ± 6.9 (0.5 µg SHU9119 and 10
µg morphine) (fig. 4).
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Figure 3. Neutralisation of the pro- and anti-
allodynic effects of MTII and morphine by
co-administration of both drugs
Effect of spinal administration of 0.5 µg of MTII (MTII
0.5) or 30 µg of morphine (Mor 30) alone, or co-
administration of 1.5 µg MTII and 100 µg of mor-
phine (MTII 1.5, Mor 100), on mechanical allodynia.
Mechanical withdrawal thresholds were assessed by
von Frey probing. Data are presented as % MPE
(mean ± S.E.M) of 8-9 rats each (MTII and morphine
alone) or 4 rats (combination of both drugs). (*
p<0.05 vs. MTII or morphine alone)
Figure 4. Additive anti-allodynic effects of
SHU9119 and morphine 
Effects of spinally administered morphine (1, 3 or 10
µg) (open circles) alone, or 15 min after 0.5 µg
SHU9119 (black circles), on mechanical allodynia.
Mechanical withdrawal thresholds were assessed by
von Frey probing. Black bar indicates the anti-allo-
dynic effect of 0.5 mg SHU9119. Data are present-
ed as % MPE  (mean ± S.E.M) of 8-9 rats each, 60
min after the last injection.
Data are presented as % MPE  (mean ± S.E.M) of
8-9 rats each. (* p<0.05 vs. morphine alone)
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Discussion
In the present study we were able to demonstrate an interaction between the
spinal MC and spinal opioid system in a rat model for neuropathic pain. In
the spinal cord, the MC4-R
28,29
, as well as α-MSH, an endogenous ligand for
the MC-R, and its precursor molecule pro-opiomelanocortin (POMC)
12,29,30
are shown to be expressed in the dorsal horn, an area involved in the pro-
cessing of nociceptive information. Proteolytic cleavage from POMC yields
not only α-MSH but also the endogenous opioid β-endorphin (βEP),
which is also present in the dorsal horn
12
. Moreover, both the µ- and δ-opi-
oid-receptors (µOR and δOR) for which βEP displays a high affinity31, are
expressed in the same area
32
.Thus both a functional MC and opioid system
appear to be present at the same anatomical site in the spinal cord. Possibly
there is a natural balance between these two systems, each with opposite
activities on nociceptive processing (see also Adan and Gispen
33
). In neuro-
pathic pain, this balance might be out of equilibrium, by increased activity
of the MC system
34
as well as decreased activity of the opioid system
19-22
.
Considering this balance between the spinal MC and opioid systems, we
proposed that by blocking the pro-nociceptive activity of the spinal MC sys-
tem with SHU9119
34
, tonic analgesic effects of βEP, through activation of
OR in the dorsal horn, will predominate (see also Vrinten et al.
35
).As shown
in figure 1, administration of naloxone increased mechanical allodynia, con-
sistent with blockade of a tonically active endogenous opioid agonist at the
spinal level.This confirms previous work, in which high doses of naloxone
increased pain-related behavior in mononeuropathic and spinally injured
rats
36,37
.When a low dose of naloxone, which by itself had no effect on allo-
dynia, was administered 15 min prior to SHU9119, the anti-allodynic effect
of SHU9119 was almost completely blocked, as can be seen in figure 2.
These data suggest that the MC and opioid systems act at the same common
pathway. Other evidence for the close interactions between the MC and
opioid system has been provided previously. For instance, chronic morphine
treatment is shown to induce a downregulation of MC4-R in several brain
areas
38
, whereas ablation of pituitary POMC neurons induces both hypo-
thalamic POMC overexpression and a downregulation of µOR in several
brain areas
39
. Our present experiments suggest that an interaction is also pres-
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ent at the spinal level. However, from these data it is not possible to establish
the neuro-anatomical origin of this interaction.The MC and opioid systems
might be organised in a linear pathway, with the MC system either up- or
downstream of the opioid system.Another possibility is that the two systems
are organised in a parallel fashion.The MC4-R and OR could be located
on different neurons, with pathways converging further downstream, or they
could be co-localised on the same neuron.The latter has been demonstrat-
ed in locus coeruleus derived cells, where α-MSH and β-EP respectively
increase and decrease the level of the second messenger cAMP (via adeny-
late cyclase) through MC-R and δOR that are expressed in the same cell40.
Adenylate cyclase might thus function as an integrator of MC and opioid
mediated signalling, thereby regulating the output of the cell in vivo. A sim-
ilar mechanism has been proposed to be involved in the effect of MCs on
opioid addiction
16
.
In order to further investigate the nature of the neuroanatomical substrate
underlying the interaction between the spinal MC and opioid system, we
tested the effect of co-administration of a high dose of the MC-R agonist
MTII and morphine.As seen in figure 3, each of this drugs alone already had
an almost maximal effect on allodynia with a 3 times lower dose than we
used for the co-administration.When the two systems are organized in a lin-
ear fashion it would be expected that the resultant effect of the combined
doses on allodynia resembles that of activation of the downstream receptor.
Thus when the OR is downstream of the MC-R, this combination of drugs
would produce anti-allodynia, and vice versa, whereas with parallel pathways
the resulting effect would expected to be in between.The net effect of the
combined drugs was indeed between those of the separate drugs (see figure
3), suggesting a parallel organization of the MC and opioid system. Since a
dose of naloxone which was in itself inactive, blocked the anti-allodynic
effect of the MC-R antagonist SHU9119, we conclude that the MC and
opioid system converge on the same pathway, possibly the same neurons,
involved in nociceptive processing. In order to address the question on
which neurons the two systems converge, it will be necessary to conduct
neuro-anatomical or electrophysiological studies.
Chapter 6
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From a clinical point of view an integration of the MC and opioid system
is interesting, since by co-administration of MC receptor antagonists it might
be possible to modulate opioid effectiveness. We tested this hypothesis by
administering SHU9119 15 min prior to morphine.With this treatment par-
adigm, SHU9119 and morphine had an additive anti-allodynic effect, as
shown in figure 4. Although this does not imply a modulation of opioid
effect by MC, it raises the possibility that combined treatment with MC4-R
antagonists and opioids might have a place in the management of neuro-
pathic pain. With concomitant administration of MC4-R antagonists, the
total  dose of opioid needed to obtain adequate analgesia might be reduced.
This might diminish the incidence and severity of opioid side effects, devel-
opment of tolerance, and possible tolerance-associated hyperalgesia
41,42
.Also,
by changing the inter-injection interval of SHU9119 and opioids, it could
be that the combined anti-allodynic action is enhanced, as has been demon-
strated for the combination of NMDA receptor antagonists and morphine
43
.
In conclusion, we were able to demonstrate an interaction between the
spinal MC and opioid systems in a rat model for neuropathic pain. The anti-
allodynic actions of the MC4-R antagonist SHU9119 were largely blocked
by a low dose of naloxone, whereas SHU9119 and morphine had an addi-
tive anti-allodynic effect. It is conceivable that co-administration of MC4-
R antagonists and opioids might contribute to a better treatment of human
neuropathic pain.
MC and opioid interaction
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Chronic neuropathic pain is a major clinical problem, since in many cases
treatment is inadequate and unsatisfactory. In the past decades our under-
standing of the pathophysiological mechanisms involved in this condition
has increased tremendously. Although a large number of clinical investiga-
tions have been performed, much of our insight into the mechanisms under-
lying neuropathic pain has come from the study of different animal models.
In the following paragraphs we discuss various aspects of these animal mod-
els, including differences between human and experimental animal situa-
tions, and the methods that are used to assess neuropathic pain in animals.
The main focus of this thesis is the role of the melanocortin system in neu-
ropathic pain.We studied this in the sciatic nerve chronic constriction injury
model of neuropathic pain. The main findings described in the preceding
chapters include plastic changes in the spinal cord MC system in these ani-
mals, and an anti-allodynic effect of blockade of the spinal MC4 receptor,
with both acute and chronic administration. Moreover, we demonstrated an
interaction between the spinal MC and opioid systems in these rats.These
results and their implications are discussed below, and suggestions for future
research are given.
1 Experimental animal models of human neuropathic pain
It is unclear to what extent animal models of neuropathic pain can be
extrapolated to the human clinical situation. A major difference between
patients and pre-clinical animal models is the extremely high incidence of
symptoms in the latter.This might be explained by the fact that experimen-
tal nerve injuries are tightly controlled in order to be reproducible whereas
in humans there is extreme variability in the extent and etiology of nervous
system injury. Genetic factors also appear to play a role, since the develop-
ment of a neuropathic pain syndrome with the same type of lesion can be
different between animal strains
1-4
.There are also genetic differences in base-
line susceptibilty to pain in animals
5,6
. Moreover, animals selected for various
phenotypes in open field activity or autotomy in a neuroma model, differ in
their likelihood to develop neuropathic pain symptoms and hyperexcitabili-
ty of sensory neurons
7-9
. Other factors that influence the development and
magnitude of a neuropathic pain syndrome are age, gender and even diet
2,10-
13
. Together, these data underscore the importance of genetic and environ-
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mental factors in neuropathic pain. Since inbred laboratory animal strains are
genetically almost identical, and experimental groups used in studies of neu-
ropathic pain are usually very homogeneous with respect to age, gender and
environment this may explain part of the discrepancies between human and
animal neuropathic pain.
In chapter 2 we describe the development of a neuropathic pain syndrome
with two types of sciatic nerve lesion, the chronic constriction injury and
the sciatic nerve crush. Both lesions were performed in young adult male
Wistar rats of the same age (8-9 weeks). Irrespective of the difference in time
course of the neuropathic syndrome between lesions, which appears to be
regeneration-related, the magnitude of sensory abnormalities was similar in
both groups. Moreover, we did not observe signs of heat hyperalgesia with
either lesion type, in contrast to other groups
14-17
.This further suggests that
homogeneity of experimental groups is an important factor in the manifes-
tation of  symptoms.
Notwithstanding the many differences between the human and animal situ-
ation, several treatment regimens derived from basic animal research have
proven to be effective in treating clinical neuropathic pain. For example,
blockade of the NMDA receptor, which plays an important role in the
development and maintenance of central sensitization, as assessed in animal
studies
18,19
was reported to have a positive effect in clinical studies
20
. Also
intrathecal administration of adenosine, a drug shown to be effective in pre-
clinical studies, has been reported to be efficacious in human neuropathic
pain
21,22
. Moreover, increased understanding of the various mechanisms
involved in neuropathic pain has yielded various drug targets, that are cur-
rently in clinical and preclinical development
23
. Thus, although they are not
perfect, the use of experimental animal models is essential, not only for
development and testing of new analgesics for neuropathic pain, but also for
increasing our understanding of the neural mechanisms involved.
2 Outcome parameters in the assessment of neuropathic pain 
2.1 Spontaneous pain
Hind paw guarding, reluctance to bear weight on the affected limb and paw
lifts unrelated to any apparent external stimulus are interpreted as signs of
spontaneous pain
24-26
.Also autotomy, the major outcome parameter in animal
Chapter 7
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models involving complete nerve transsection, such as Wall’s neuroma
model
27
, has been used as an index of spontaneous pain
28-30
. It can be difficult
to quantify these manifestations of spontaneous pain and to exclude that
these responses are evoked by indistinct external stimuli such as floor con-
tact. Moreover, the question whether autotomy is an expression of sponta-
neous pain or rather reflects an attempt of the animal to get rid of an den-
ervated body part is still a matter of debate
31,32
.Therefore, most studies focus
on stimulus-evoked pain, by investigating the animal’s response to various
mechanical, temperature or chemical stimuli.
2.2 Stimulus-evoked pain
2.2.1 Thermal stimulation 
Increased sensitivity to various thermal stimuli is often employed to study
neuropathic pain in animals. Measurements of cold allodynia include the
number of foot withdrawal responses after application of acetone
25
or ethyl
chloride
33
to the plantar surface of the paw. Heat hyperalgesia can be quan-
tified by determining withdrawal latencies to a radiant heat source, or a CO2
laser
34,35
.This is however a costly method. Another frequently used and easy
method is determining the withdrawal latency or total duration of paw lift-
ing or upon placement on a cold or hot plate
35-37
. A potential drawback of
this approach is a paw withdrawal in response to the mechanical stimulus of
touching the floor rather than to the temperature stimulus, since heat hyper-
algesia and cold allodynia are often accompagnied by mechanical allodynia.
Therefore we chose to investigate the effect of temperature stimulation by
immersion of the animals paw into a water bath, to minimize any influence
of mechanical hypersensitivity.This method has also been used by others
16,17
.
In our experimental setup we included an electronical timer with was auto-
matically started upon immersion of the paw and stopped upon withdraw-
al.This allowed for a rapid and semi-automated quantification of withdraw-
al latencies upon thermal stimulation.
A possible disadvantage of paw immersion in a water bath is that it is not
possible to limit the skin area to which the stimuli are applied to the sciatic
nerve’s territory, since the whole paw is immersed. Therefore it cannot be
excluded that changes in sensitivity are caused by alterations in adjacent
intact nerves, such as the saphenous nerve, innervating the medial dorsal part
General discussion
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of the hind paw, as has been suggested by Kingery and colleagues
38
. However,
with careful registration of the time course of responses to thermal stimuli
and comparison with responses to other stimuli that can be limited to the
sciatic nerve’s territory, such as von Frey probing, these problems can be cir-
cumvented (see also chapter 2).
The waterbath immersion test as we described here can thus be used as a
rapid and semi-automated method to quantify responses to various thermal
stimuli in animals.
2.2.2 Mechanical stimulation
Hypersensitivity to mechanical stimuli is most commonly assessed by means
of probing with von Frey filaments. Although the bending forces of these
filaments are very reproducible and inter- or intra-experimenter variability
is low
39
, there are some problems with this method. Apart from possible
effects of temperature, ambient humidity and extensive use on bending
forces
40,41
, the many ways in which filaments are applied and withdrawal
thresholds are determined makes it very difficult to compare results obtained
from different studies.
In chapter 3 we compared mechanical withdrawal thresholds determined by
von Frey filaments with different parameters of locomotion obtained by
CatWalk analysis.With the CatWalk method data acquisition is performed
by computer, thus making it a fast and objective method.We found a very
high degree of correlation and parallel time courses between von Frey
thresholds and pressure applied by the experimental hind paw during loco-
motion, suggesting that both parameters might reflect mechanical allodynia.
Indeed, a decrease in applied pressure has also been described in inflamma-
tory pain, a condition associated with mechanical allodynia
42
, and decreased
weight bearing of the limb has been shown to be present in neuropathic
conditions
26
.We also observed a significant decrease in the duration of the
stance phase, probably reflecting a reluctance of the animal to place the
affected paw on the floor.This parameter also had a similar time course and
a high correlation with von Frey thresholds. It is not likely that these high
correlations and parallel time courses between von Frey thresholds, stance
phase duration and pressure merely reflect a recovery from locomotor
deficits. Nervous system injuries associated with locomotor deficits exhibit
Chapter 7
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an increase in pressure and stance phase rather than a decrease
43-45
. Moreover,
as described in in chapter 2, we found no correlation between locomotor
recovery and resolution of mechanical allodynia in CCI rats.Therefore we
hypothesise that the pressure and stance phase parameters obtained by the
CatWalk method indeed reflect the magnitude of mechanical allodynia. It
would be useful to conduct an experiment with anti-allodynic drugs, to
investigate whether these CatWalk parameters are indeed altered, to further
confirm the usefulness of CatWalk analysis as a measure of mechanical allo-
dynia.
3 Melanocortins in neuropathic pain 
3.1 Plasticity of the spinal MC system 
Plastic changes in spinal cord and DRG receptors following nerve lesions have
been described for many receptors, including opioid (see below), vanilloid46,
metabotropic glutamate (DRG)47, galanin48 and GABA receptors49. In chapter
4 we demonstrated that spinal MC receptors also undergo plastic changes in
CCI rats, as demonstrated by a 25% increase in in situ 125I-NDP-MSH bind-
ing to spinal cord dorsal horn as compared to sham operated animals. Since
the only known MC-R subtype present in the spinal cord is the MC4-R, this
increased binding most likely represents an upregulation of the spinal MC4-R
This increase is not robust, but its magnitude is comparable to the changes
observed in for instance opiate receptor levels upon nerve injury. Quantitative
autoradiography demonstrated an initial increase in dorsal horn µOR of 29%,
2 days after a chronic constriction injury
50
, followed by a long-lasting decrease
of 28% 
51
. De Groot et al found a 17-49% decrease in µOR immunoreactivi-
ty two weeks after axotomy
52
. Similarly, Zhang and colleagues found a 30 –50
% decrease in µOR immunoreactivity in the rat dorsal horn in the same
model
53
. In the monkey however, this decrease was much larger, indicating that
there are species differences in µOR plasticity upon nerve damage53. Similarly,
differences between monkey and rat have also been described for plastic
changes in galanin in the dorsal horn after axotomy, this upregulation being far
greater in the monkey
48
. This suggests that, after nerve injury, some plastic
changes in the spinal cord are more pronounced in primates (including
humans?) than in the rat. At present it is not known whether this also holds
true for upregulation of spinal MC receptors.
General discussion
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3.2 The spinal MC4 receptor in neuropathic pain
In spite of the relatively small increase in spinal MC-R, we showed that
blockade of these receptors by SHU9119 reduces symptoms of neuropathic
pain in CCI rats, whereas activation by MTII and D-Tyr-MTII had the
opposite effect (chapters 4 and 5). Also the more selective MC4-R agonist
JK1 increased neuropathic pain symptoms
54
, further confirming that these
effects are mediated through the MC4 receptor.
In these experiments ligands  were administered through a cisterna magna
cannula, directly into the cerebrospinal fluid surrounding the spinal cord.
Chronic administration of SHU9119 and MTII had no effect on body-
weight, and a single high dose of MTII induced no grooming behaviour,
both centrally mediated MC effects (for review, see Adan and Gispen
55
).This
suggests that the observed effects of MCs in neuropathic pain are mediated
at the spinal level. From these experiments the possibility that these effects
are (in part) mediated at the level of the brainstem, an area where MC4
receptors are also located
56
, cannot be excluded. However, the only
somatosensory area in the brainstem containing MC4 positive cells is the
caudal part of the spinal nucleus of the trigeminal nerve
56
. Moreover, by
using a lumbar spinal catheter as the route of administration, thus limiting
the spread of ligands to the lumbar spinal cord
57
, similar results are obtained
(see chapter 6), further pointing at a spinal site of action.
The early reports describing melanocortin-induced hyperalgesia demon-
strated decreased withdrawal latencies to a noxious heat stimulus upon
administration of α-MSH or ACTH
58-60
. In contrast, we found no effects of
MC4-R agonists on withdrawal latencies to a heat stimulus in control rats.
This might be explained by the fact that in these aforementioned studies
melanocortins were administered intracerebroventricularly, whereas we
administered ligands at the spinal level, indicating that brain and spinal
melanocortin systems might have different effects on nociception.
In summary, our data suggest that the effects of melanocortins on neuro-
pathic pain symptoms are mediated through the spinal MC4 receptor.
3.3 Modulation of sympathetic activity
The mechanism underlying the effects of melanocortins on nociception is
not known. As already mentioned in chapter 4, one possibility is that these
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effects are exerted through a modulation of sympathetic activity. It has been
demonstrated that central administration of α-MSH or ACTH increased
sympathetic outflow and lumbar sympathetic nerve activity
61,62
. I.c.v. admin-
istration of the MC-R agonist MTII also increased sympathetic activity, and
this effect could be blocked by SHU9119
63
. These effects are likely to be
mediated through the MC4-R
56,61
.
In the experiments descibed in chapter 4 we demonstrated an upregulation
of MC4-R at the lumbar spinal level, but we cannot exclude the possibility
that upregulation also occurs at other levels of the spinal cord, e.g.more ros-
trally. Here the intermediolateral nucleus, containing cell bodies of the pre-
ganglionic sympathetic fibers, is located. MC4-R positive cells have been
demonstrated in this nucleus, colocalised with choline acetyltransferase, indi-
cating that these neurons are cholinergic in nature (J. Elmquist, personal
communication). By using a cisterna magna cannula or a lumbar spinal
catheter, drugs are allowed to spread over several spinal segments, thus it is
possible that in our experiments sympathetic outflow is modulated.
It has been long known that sympathetic activity can contribute to certain
types of neuropathic pain, and sometimes patients benefit from sympathetic
blockade  (for review, see Janig and Baron
64
).Various studies in animal mod-
els have demonstrated adaptations in the sympathetic nervous system in neu-
ropathic pain, and accumulated evidence for the development of a function-
al sensory-sympathetic coupling
64,65
.After partial nerve injury, primary affer-
ent fibers may begin to express α-adrenoreceptors, thus rendering them sen-
sitive to sympathetic stimulation and norepinephrin
23,35
. Nerve injury also
induces sprouting of sympathetic axons into the dorsal root ganglion, where
they form baskets around the cell bodies of sensory neurons
23,66,67
. Its rele-
vance in neuropathic pain is however not clear, since Kim and colleagues
found no correlation between the magnitude of neuropathic pain symptoms
and the extent of sympathetic sprouting
68
(see also Michaelis
65
). Moreover,
the effect of sympathicolysis in animal models of neuropathic pain is highly
variable
69-71
, and has very little effect in the CCI model
35,72,73
. It has been sug-
gested that mechanisms other than sympathetic changes are more important
in the CCI model
74
.
Therefore we hypothesize that the effects of MCs on allodynia are not medi-
ated through modulation of sympathetic activity, but that other mechanisms
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are involved. In view of the presence of both α-MSH and β-endorphin,
both derived from POMC, in the dorsal horn, and the abundant evidence
pointing at an interaction between the melanocortin and opiate system (see
chapter 6), an interaction with the spinal opiate system is a possible candi-
date mechanism.
4 Melanocortins and the opiate system
Opioids are the cornerstone in the treatment of severe pain, but their effec-
tiveness in neuropathic pain has been a matter of debate for many years.
Several clinical studies have demonstrated a lack of potent analgesic efficacy
of opioids in neuropathic pain
75,76
. On the other hand, various studies
demonstrated pain relief with opioid treatment (for review, see
Rowbotham
77
), and it is now generally believed that neuropathic pain is not
opioid-resistant but there merely is a reduced sensitivity to these drugs. Thus
in order to obtain adequate pain relief higher doses of opioids are needed
78,79
,
thus their use is often limited by unwanted side-effects
80
.
There are several possible explanations for this rightward shift in the opioid
dose-response curve, such as a loss of opioid receptors after nerve injury (see
above, paragraph 3), or an upregulation of the endogenous opioid function-
al antagonist cholecystokinin
81,82
. In view of the known functional antago-
nism between the MC and opioid system (see chapter 1), we hypothesized
that the plasticity in the spinal MC system in neuropathic pain we observed
83
might also contribute to the decreased opioid efficacy.
In parallel with the clinical situation, the analgesic effect of opioids is also
decreased in animal models of neuropathic pain. Several experimental stud-
ies have demonstrated only a weak or absent analgesic effect of intrathecal-
ly administered morphine in these models
84-87
. In our experiments intrathe-
cally administered morphine was effective, but the doses we used (approxi-
mately 30-90 µg/kg bodyweight) were very high when compared to the
human situation, also pointing at a rightward shift of the dose-response
curve.
As described in chapter 6, we investigated whether it is possible to increase
opioid sensitivity through modulation of the spinal MC system activity.We
suggest that there is a functional interaction between the spinal MC and opi-
ate system, as demonstrated by a blockade of the anti-allodynic effect of
Chapter 7
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SHU9119 by pretreatment with a low dose of naloxone, which by itself had
no effect on allodynia.
In our experiments we found no indications for synergistic anti-allodynic
effects of SHU9119 and morphine, since when SHU9119 was given 15 min
prior to morphine, the effects of both drugs were additive.When morphine
and SHU9119 were given simultaneously, this additive effect of SHU9119
was however not observed. Different treatment  strategies have been
described in other studies demonstrating synergism between morphine and
other drugs, in either neuropathic or non-neuropathic conditions. For
instance, synergistic anti-allodynic effects have been described with coad-
ministration of ketorolac or neostigmine and morphine
87,88
, paracetamol 10
min before or diltiazem 30 min before morphine
89,90
or with gabapentin two
hours after morphine
91
. Apparently, the relative timing of administration of
both drugs is important. This has also been suggested by Belozertseva and
colleagues
92
, who demonstrated that the ability of NMDA receptor antago-
nists to affect morphine antinociception depends on the inter-injection
interval. In this regard it is possible that other treatment regimens, e.g. a
longer interval between SHU9119 and morphine, or repeated administra-
tion of SHU9119 prior to morphine, will give different, possibly synergistic,
results.
As described in chapter 4, we propose that the anti-allodynic effects of
SHU9119 are caused by blockade of a tonic MC4-R activation by endoge-
nous α-MSH, thus disclosing the tonic analgesic effects of βEP which is co-
released with α-MSH in the spinal cord. Possibly, the rapid decline of the
anti-allodynic effects upon chronic administration of SHU9119, as seen in
chapter 5, reflects the development of tolerance for the endogenous opioid
βEP, instead of tolerance for SHU9119.
This rapid development of tolerance does however not preclude MC4
receptor antagonists for possible clinical use. As is the case with differences
in the susceptibility to neuropathic pain syndromes (see above, paragraph 1),
there are also differences in sensitivity to morphine and the development of
tolerance between animals
93
. Moreover, there are large differences in the
development of tolerance between animals and humans. In animal studies,
morphine tolerance can develop already within a few days, or even after a
single dose
94-97
, whereas in humans long-term opioid therapy can be success-
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ful
98-100
(see also Rowbotham
77
and chapter 5). .Mayer and colleagues suggest-
ed that repeated administration of morphine could not only lead to the
development of tolerance but contribute to hyperalgesia as well
101,102
. This
might initiate a vicious cycle, leading to progressively higher opiate doses,
and subsequently more tolerance and hyperalgesia.With polypharmacy reg-
iments, combining two analgesic drugs with additive effects such as
SHU9119 and morphine, it might be feasible to obtain adequate analgesia
with a lower total dose of opioids.This would reduce opioid-therapy relat-
ed problems such as adverse effects, development of tolerance and tolerance-
associated hyperalgesia. Moreover, treatment with MC4-R antagonists might
be a useful “add-on” therapy, considering the reduced opioid responsiveness
present in neuropathic pain states.
5 Potential avenues for future research.
From the work presented in chapter 4 and 5, we conclude that both acute
and chronic intrathecal administration  of the MC-R antagonist SHU9119
alleviates symptoms of neuropathic pain in the rat chronic constriction
injury model. We hypothesise that these effects are mediated through the
spinal MC4-R. Since the endogenous MC-R agonist α-MSH is co-released
with the endogenous opioid β-EP in the spinal cord, we  hypothesise that
the anti-allodynic effects of MC-R blockade are caused by disturbance of a
balance between the MC and opioid system, allowing the anti-allodynic
effects of β-EP to predominate. Indeed, an interesting finding in this thesis
was an interaction between the spinal MC and opioid system, as demon-
strated by a blockade of the antiallodynic effects of SHU9119 by a low dose
of naloxone, which by itself had no effect on allodynia (see chapter 6).We
could however not provide an anatomical basis for this interaction.Therefore
this finding would be greatly supported by neuroanatomical studies, direct-
ed at the neural circuitry underlying these effects.
Since no MC4-R mRNA could be demonstrated in DRG neurons, its pres-
ence in the dorsal horn is not likely to be from primary afferent origin
103
.An
in situ hybridisation study has demonstrated MC4-R positive neurons in the
spinal cord dorsal horn (Elmquist, J., personal communication). Both the µ-
and δOR, for which β-endorphin has high affinity, are known to be
expressed in the dorsal horn
104-106
. Although the δOR is suggested to play a
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Figure 1.
Schematic summary of the possible anatomical organisation of the spinal melanocortin and opioid
systems, relative to sP-containing primary afferents in the dorsal horn. A dorsal horn second-order
neuron is depicted, which is activated by substance P (sP) and glutamate (glu) released from primary
afferents upon noxious stimulation.These postsynaptic responses could be modulated through acti-
vation of the melanocortin-4-receptor (MC4R) and m-opioid receptor (µOR) which are opposite-
ly coupled to the adenylate cyclase pathway (AC). In addition, sP release is also inhibited through acti-
vation of presynaptic mOR. Sites of action of various ligands affecting neuropathic pain symptoms are
also indicated (i.e. MTII, SHU9119 and opioids). For further details, see text.
DAG: diacylglycerol, IP3: inositol triphosphate, NK1-R: neurokinin-1-receptor, β-end: β-endorphin,
POMC: pro-opiomelanocortin.
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role in antinociception at the spinal level (see Przewéocki
107
), the analgetic
effects of opioids, including βEP and morphine, are mostly mediated
through the µOR108-110 and almost all clinically available opioids are µ-selec-
tive ligands
111
.Therefore, in future studies into the neuroanatomical basis for
the interaction between the spinal MC and opioid system, it appears logical
to focus on the µOR.
In the dorsal horn, the µOR is localised both pre- and postsynaptical-
ly
104,112,113
. Several lines of evidence have suggested that opioid analgesia is
mediated through presynaptic inhibition of stimulation-induced substance P
(sP) release from primary afferents
114-117
. However, only few primary afferents
exhibit opioid receptor and sP co-localisation
113,118
. Moreover, noxiously
evoked sP release from primary afferent origin in the dorsal horn of the cat
was unaffected by superfusion with high concentrations of morphine
119
.
Many of the µOR positive dendrites in the dorsal horn co-localise with the
sP receptor NK1
120
, and µOR internalisation in dorsal horn neurons corre-
lates with the level of analgesia produced by the µ-OR agonist DAMGO121.
These observations have led to the suggestion that µOR ligands modulate
sP mediated nociceptive responses predominantly through inhibition of
postsynaptic excitatory neurons
120-122
. Indeed, electrophysiological studies
have revealed a hyperpolarisation of substantia gelatinosa neurons by
DAMGO
123-125
. More specifically, Cheunsuang and colleagues have reported
similar results in NK1-positive neurons
126
, further confirming that opioid
analgesia involves inhibitory mechanisms postsynaptic of sP input. Possibly
the neurons that are inhibited by µOR agonists also contain sP, considering
the reported co-localisation of the µOR and sP in dorsal horn neurons118.
Thus, since postsynaptic µORs appear to play a role in antinociception
through inhibition of excitatory interneurons and both the µOR and the
MC4-R are localised on local dorsal horn neurons, it is conceivable that they
are co-localised on the same cells, which could be containing sP.
Hypothetically, the output of these excitatory neurons, involved in nocicep-
tive transmission, might be increased by MC4-R activation and decreased by
µOR activation.At present there are no good MC4-R antibodies available;
therefore one possible neuroanatomical approach to solve this question
might be to combine MC4-R in situ hybridisation with µOR (and sP)
immunohistochemistry to demonstrate a possible co-localisation of both
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receptor types. Doublestaining for the sP receptor NK1 might demonstrate
whether the MC4 positive neurons are localised post-synaptically of the sP
containing afferents, as is the case for the µOR120. Since upon noxious stim-
ulation, c-Fos protein is induced in postsynaptic spinal cord neurons
17,127-129
,
including NK1-positive neurons
130
, c-Fos staining combined with labelling
of the MC4 (and NK1) will provide further assessment of the role of MC4-
positive neurons in the nociceptive pathways in the spinal cord.
Electrophysiological studies, investigating the effects of combinatined
administration of MC4 receptor and µOR ligands on excitatory transmis-
sion in dorsal horn neurons could allow further elucidation of the underly-
ing mechanism of the MC and opioid system interaction (see also figure 1).
In our experiments we demonstrated additive anti-allodynic effects of
SHU9119 and morphine. However, as discussed above, it is possible that
other treatment strategies could further enhance the anti-allodynic effects of
this combined treatment. Therefore it will be interesting to test different
administration paradigms.Also, since intrathecal catheters are not first choice
options in clinical practice, it will be worthwhile to investigate other routes
of administration. Moreover, considering the known functional antagonism
between the MC and opioid system, it will be interesting to investigate
whether modulation of the activity of the spinal MC system could influence
the development of opioid tolerance.
In conclusion, the studies described in this thesis, concerning the role of the
spinal MC system in neuropathic pain and its interaction with the spinal opi-
oid system, are clearly just the beginning of a new lead in the putative phar-
macotherapy of neuropathic pain. From a clinical perspective these results
are promising and merit further study, since MC4-R antagonists and possi-
bly combined therapy with opioids might aid to the relief of human neuro-
pathic pain.
General discussion
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Nederlandse samenvatting
Neuropathische pijn is gedefinieerd als “pijn veroorzaakt door een lesie of
dysfunctie van het zenuwstelsel”. Kenmerkende symptomen zijn allodynie
(pijn als reactie op een normaliter niet-pijnlijke prikkel) en hyperalgesie
(toegenomen pijn als reactie op een pijnlijke prikkel). Dit pijnsyndroom is
vaak moeilijk te behandelen en reageert over het algemeen onvoldoende op
pijnstillers als NSAIDs en opiaten.
In hoofdstuk 1, de inleiding van dit proefschrift, wordt een overzicht
gegeven van neuropathische pijn, waarbij met name wordt ingegaan op de
classificatie, symptomatologie, verschillende experimentele diermodellen en
tot nu toe bekende  pathofysiologische mechanismen.Verder wordt er dieper
ingegaan op de mogelijke betrokkenheid van het melanocortine-systeem bij
dit type pijn.
Melanocortines zijn peptiden zoals het α-melanocyt-stimulerend hormoon
(α-MSH) en adrenocorticotroop hormoon (ACTH), en daaraan gerela-
teerde peptiden. Ze zijn betrokken bij tal van fysiologische processen zoals
pigmentatie, inflammatie, zenuwregeneratie en energiemetabolisme. Er zijn
ook aanwijzingen dat melanocortines functionele antagonisten van het opi-
aat systeem zijn, en dat ze invloed hebben op pijngedrag in proefdieren. De
precieze basis van deze effecten is echter onbekend.
In dit proefschrift wordt de mogelijke rol van het melanocortine-systeem in
neuropathische pijn onderzocht. Hiertoe werd gebruikt gemaakt van een
diermodel: het “chronic constriction injury (CCI)” model in de rat.
In hoofdstuk 2 worden het CCI model en de verschillende uitleesparame-
ters van dit model gevalideerd. In dit model worden een viertal losse liga-
turen rond de nervus ischiadicus gelegd. Hierdoor ontstaan zwelling en ver-
hoogde druk in de zenuw en sterft een groot deel van de zenuwvezels af.
Dieren met een CCI letsel ontwikkelen na enkele dagen symptomen die
sterk lijken op de klinische uitingen van neuropathische pijn, zoals een ver-
sterkte reactie op verschillende normaal niet-pijnlijke of pijnlijke prikkels
(allodynie en hyperalgesie). Deze symptomen werden gekwantificeerd door
de reacties van de dieren op applicatie van kou, hitte, mosterdolie en von
Frey filamenten op de achterpoten te meten.
Samenvatting
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We hebben ratten met een CCI letsel vergeleken met het crush-letsel van de
nervus ischiadicus, een veelgebruikt model voor zenuw-regeneratie onder-
zoek. Beide typen letsels veroorzaakten, naast een verstoring van de loco-
motor-functie, tekenen van allodynie en hyperalgesie. In het CCI model
onstonden deze symptomen al binnen enkele dagen na het aanbrengen van
het letsel, terwijl ze in het crush-model pas optraden na regeneratie van de
zenuw en herstel van locomotie. Deze resultaten suggereren dat een crush-
letsel ook kan dienen als een additioneel diermodel voor neuropathische
pijn,met een ander tijdsverloop en onderliggend zenuwletsel dan in het CCI
model.
Een veelgebruikte methode om mechanische allodynie te kwantificeren is
de bovengenoemde applicatie van von Frey filamenten. Hoewel dit een
reproduceerbare methode is, zijn er toch enkele nadelen aan verbonden;
testprocedures en definities van drempelwaarden komen niet altijd overeen.
Daarnaast zijn de filamenten zelf gevoelig voor diverse invloeden, zoals tem-
peratuur, vochtigheidsgraad en slijtage door veelvuldig gebruik. In hoofdstuk
3 hebben we een alternatieve methode voor het meten van mechanische
allodynie onderzocht: de CatWalk. Dit is een systeem, recent ontwikkeld op
ons laboratorium, waarbij locomotor-parameters automatisch gekwan-
tificeerd kunnen worden.We hebben gekeken naar de duur van de verschil-
lende fasen van de stap-cyclus en de hoeveelheid druk die door de achter-
poten uitgeoefend wordt tijdens het lopen. Het bleek dat dieren met een
CCI letsel minder druk uitoefenen met de aangedane achterpoot en dat de
duur van de stand-fase van deze poot significant verkort is. Er was een sterke
correlatie tussen deze parameters en de mechanische drempelwaarden geme-
ten met de conventionele von Frey methode. Dit wijst erop dat analyse van
relevante CatWalk parameters mogelijk gebruikt zou kunnen worden in het
onderzoek naar mechanische allodynie.
In hoofdstuk 4 en 5 is de betrokkenheid van het melanocortine-systeem in
neuropathische pijn bestudeerd.Tot dusver zijn er vijf verschillende subtypen
melanocortine-receptoren bekend. Hiervan is de melanocortine-4-receptor
(MC4-R) de enige die voorkomt in het ruggenmerg, en met name in
gebieden die betrokken zijn bij het verwerken van pijnsignalen (nocicepsis),
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waaronder de dorsale hoorn.
We hebben aangetoond dat de hoeveelheid binding van 125I-NDP-MSH, een
radioactief gelabeld α-MSH derivaat, in de dorsale hoorn is toegenomen in
CCI dieren. Dit wijst op plastische veranderingen in het spinale melanocor-
tine-systeem en waarschijnlijk een toename van het aantal spinale MC4
receptoren in neuropathische pijn. Door middel van spinaalcatheters hebben
we verschillende melanocortines rechtstreeks in de liquor rondom het
ruggenmerg toegediend, zowel acuut als chronisch (m.b.v. een subcutaan
geïmplanteerde osmotische minipomp), en de effecten hiervan op de symp-
tomen van neuropathische pijn onderzocht in het CCI model. Onze resul-
taten laten zien dat activatie van de MC4 receptor, door middel van ver-
schillende agonisten, de symptomen versterkt, terwijl blokkade van deze
receptor, door middel van de antagonist SHU9119, de symptomen vermin-
dert. Dit bevestigt dat het melanocortine-systeem inderdaad betrokken is bij
nocicepsis, en meer specifiek bij neuropathische pijn.
Het feit dat toediening van de MC receptor antagonist SHU9119 op
zichzelf een effect heeft suggereert dat het melanocortine-systeem tonisch
pro-nociceptief actief is, waarschijnlijk via de endogene MC receptor ago-
nist α-MSH die aanwezig is in de dorsale hoorn. Blokkade van deze
activiteit, door SHU9119, onthult mogelijk een tonisch anti-nociceptief sys-
teem wat zorgt voor de vermindering van symptomen.We veronderstellen
dat dit het spinale opiaat systeem betreft. Er zijn een tweetal redenen voor
deze veronderstelling: 1) er is reeds bekend dat het melanocortine- en opi-
aat-systeem functioneel antagonisme vertonen en 2) β-endorfine, een endo-
gene agonist voor de opiaat receptor, is afkomstig van hetzelfde voorloper-
molecuul als α-MSH en is ook aanwezig in de dorsale hoorn.
Mogelijk bestaat er in het ruggenmerg dus een balans tussen de pro-noci-
ceptieve activiteit van het melanocortine-systeem en de anti-nociceptive
activiteit van het opiaat systeem, en beïnvloeden deze systemen elkaar. Deze
hypothese wordt in hoofdstuk 6 onderzocht. Hier tonen we aan dat spinale
toediening van naloxon, een opiaat receptor antagonist, de symptomen van
neuropathische pijn verergert, wat suggereert dat het opiaat systeem inder-
daad tonisch anti-nociceptief actief is. Een zeer lage dosis naloxon, die op
zichzelf geen effect had, was in staat om het anti-nociceptive effect van
SHU9119 volledig te blokkeren. Dit bevestigt onze hypothese dat er een
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interactie bestaat tussen het melanocortine en opiaat systeem in het ruggen-
merg. De precieze neuro-anatomische basis voor deze interactie dient nog
verder onderzocht te worden.
Daarnaast hebben we gekeken naar het effect van gecombineerde behandel-
ing met SHU9119 en morfine, een opiaat receptor agonist. We hebben
aangetoond dat de effecten van deze twee stoffen additief zijn.
Al deze resultaten tezamen worden tenslotte in hoofdstuk 7 bediscussieerd
en suggesties voor verder onderzoek worden gegeven. Op basis van de
experimenten beschreven in dit proefschrift menen wij dat behandeling met
MC4 receptor antagonisten in de toekomst eventueel een plaats verdient in
de behandeling van neuropathische pijn. De interactie met het opiaat sys-
teem is interessant, gezien de verminderde effectiviteit van opiaten in neu-
ropathische pijn. Een toegenomen activiteit van het melanocortine-systeem
zou mede ten grondslag kunnen liggen aan deze verminderde effectiviteit,
en toediening van een combinatie van opiaten en MC4 -receptor antago-
nisten zou mogelijk bij kunnen dragen aan een adequate behandeling van
dit pijnsyndroom.
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ik nog nooit gehoord. Ik ben dus grote dank verschuldigd voor het in
mij gestelde vertrouwen, en voor de kans die ik gekregen heb om in
dit project te groeien. En dat bleke meisje met de rode haren, daar
gaan we nu maar eens “een goede anesthesist van maken”….
Jan Brakkee, je bent met name in de beginfase zeer betrokken geweest bij
mijn onderzoek. Ik heb grote waardering voor je enthousiame, cre-
ativiteit en je ongeëvenaarde kunst om heel veel te bereiken met een-
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je hulp bij alle operaties, en voor de gezelligheid tijdens de pauzes. Ik
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Voor een digibeet als ik grenst jouw IT vaardigheid aan tovenarij; ik
vind het indrukwekkend wat je met het ontwikkelen van de
“CatWalk” gepresteerd hebt.Aangezien ik significant weinig verstand
heb van statistiek, ben ik ook bijzonder blij dat ik altijd bij je langs kon
komen voor advies.
Leo van Halewijn, Tom Roeling en Jan Willem de Groot. Toen ik uren
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te vegen twijfelde ik toch even aan mijn roeping als wetenschapper.
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gische trukendoos los te laten, waarvoor dankjewel. Jan Willem en
Tom, ook jullie bedankt voor jullie hulp bij de niet altijd even suc-
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cesvolle kleuringen, en voor mijn introductie in  “de magie van het
slede-microtoom”.
Dank ook aan alle 374 ratten die geheel onbaatzuchtig hun leven hebben
gelaten voor dit onderzoek. Laten we hopen dat het niet voor niets is
geweest. In ieder geval zijn ze tijdens hun soms korte levens optimaal
verzorgd en vertroeteld door de dierverzorgens (Wout Puijk en Bert
Tersteeg), waarvoor mijn hartelijke dank! 
Keith Garner en Nienke Wanders, dank voor jullie hulp bij een aantal van
mijn experimenten.
Alle andere RMI-ers (en in het bijzonder mijn oud-kamergenoten Hikke,
Marjan en Elisabeth): mede dankzij jullie heb ik een bijzonder leuke
tijd gehad, die ik voor geen goud had willen missen.
Al mijn collega-assistenten, stafleden en medewerkers bij de anesthesiologie.
Ook tijdens mijn lange periodes op het lab heb ik nog gewoon het
gevoel gehad dat ik bij de anesthesie hoorde en dat ik zó weer in kon
stappen. Dankjulliewel voor alle geduld en interesse. Ik beloof dat ik
me in het vervolg gewoon, net als jullie, bezig zal houden met patiën-
ten in plaats van ratten, zoals het hoort...
Mijn beide paranimfen Sanne en Paul, wat fijn dat jullie me in deze span-
nende tijden terzijde willen staan. (Ik hoop niet dat ik letterlijk op jul-
lie terug hoef te vallen, maar mocht het nodig zijn......). Paul, ik denk
dat we hierna wel een grote fles Grand Marnier verdiend hebben,
toch? Sanne, alle geluk in de toekomst, enneh.....opleiding, promotie
en verder: je kunt het!
Mijn lieve zus Cécile, geweldig grote dank voor je hulp met de lay-out en
het ontwerp van het kaftje (toch wel het meest geziene deel van een
proefschrift....). Ik wens je heel veel geluk in Amsterdam! 
Jamila, mijn grote vriendin en “mi casa es su casa”-buurvrouw, dankjewel
Dankwoord
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voor je gezelligheid, luisterend oor en culinaire ondersteuning (post-
op hemelse modder?) 
Dank, Rob, voor opbeurende e-mail vol fraaie haiku’s en kreupelrijm, alsmede
de makers van freecell en Outlook express voor de veelvuldige momenten
tussen tiepen en testen door.
Mijn lieve ouders.Van concertvleugel via pipet naar beademingstoestel: jul-
lie hebben me voortdurend gesteund in al mijn keuzes, en ongelofe-
lijk veel voor me mogelijk gemaakt. Hiervoor mijn onbeschrijfelijk
grote dank! Mam, je bent ook nog eens de beste oppas-oma die een
kleinkind zich wensen kan.
Ook Bep en Mariet: dankjulliewel voor alle interesse, en voor de oppas op
de momenten dat het allemaal echt te druk werd.
Tenslotte: deze onderzoeksperiode heeft me zoveel meer opgeleverd dan
alleen een promotie… Wouter en Merijn, ik ben bijzonder blij dat jul-
lie in mijn leven gekomen zijn!
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